[{"text": "Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential Noor Ul Ain Rehman Fri, Jan 17, 2025, 7:18 PM 5 min read In This Article: DNLI -6.27% We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential . In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ: DNLI ) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech Stocks While 2024 was a \u201cchallenging\u201d year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months. On November 28, Johan Hueffer, senior partner and principal of investments at Novo Holdings, appeared on CNBC to discuss his macro perspective on investments in life sciences. He said that biotechs faced difficulty raising capital in the last couple of years. However, that trend has started to improve in the last quarter or two. Still, there have been impacts on companies that particularly service the pharmaceutical industry, such as contract research organizations (CROs), contract manufacturing organizations (CMOs), and companies that provide tools for research and development. Similar trends have been observed for companies that manufacture tools for production in the pharmaceutical and biotech industries. While these sectors have had ups and downs in the past two years, the trends are starting to normalize now. Hueffer was of the view that the industry is now showing considerable opportunity. The Fed\u2019s Rate Cuts and Biotech Stocks: Could There Be a Connection? Similarly, Goldman Sachs shed light on biotech as an often overlooked sector in the investing space. In a note to clients, John Flood, Goldman\u2019s Head of Americas Equities Sales Trading, said that biotech stocks posed an under-the-radar opportunity for investors looking to capitalize on the Fed\u2019s recent rate cuts. Changes in interest rates uniquely affect biotech stocks as they are sensitive to them and often rely on projected future profits. These stocks are also heavily impacted by the cost of capital. Although there is little to no current profitability, these stocks have significant upside potential and pose an \u201coption-like structure\u201d if clinical trials succeed. This makes them especially responsive to changes and movements in interest rates. Since September, the Fed cut a full point off the funds rate. According to CNBC, the current market pricing is showing just one or two more moves lower in 2025. On January 8, CNBC reported that the Federal Open Market Committee (FOMC) members voted to reduce the central bank\u2019s benchmark borrowing rate to the 4.25%-4.5% target range. However, they also slashed their outlook for expected rate cuts for 2025, bringing it down to two from four and assuming quarter-point increments. These changes are expected to affect biotech stocks. Story Continues Flood\u2019s note also highlighted that the biotech industry has recently shown improved fundamentals, attributed to a more favorable regulatory environment and positive clinical outcomes. Despite these tailwinds, Goldman\u2019s data reflects that biotechnology remains under-owned by hedge funds. The sector ranked in the 13th percentile in hedge fund long/short positioning over the past year. Furthermore, it ranked in the 4th percentile over the past five years. Our Methodology We used the Finviz stock screener to compile a list of 40 biotech stocks. We then selected the top 12 stocks with the highest analyst upside potential as of January 15, 2025. We have also included the market capitalization of the stocks as of the same date. The list is sorted in ascending order of analysts\u2019 average upside potential. These stocks are also popular among elite hedge funds, as of fiscal Q3 2024. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small cap and large cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). 12 Biotech Stocks with the Biggest Upside Potential A doctor examining a patient's brain scan in a hospital setting displaying a neurological disorder. Denali Therapeutics, Inc. (NASDAQ: DNLI ) Analyst Upside: 89.71% Number of Hedge Fund Holders: 23 Denali Therapeutics, Inc. (NASDAQ:DNLI) develops and commercializes product candidates for neurodegenerative diseases. Its product portfolio includes LRRK2, RIPK1, TREM2, and Tau. The company expects to submit its first biologics license agreement (BLA) for tividenofusp alfa for Hunter syndrome and prepare for commercial launch. It is also seeking alignment with the FDA to attain an accelerated approval path for its second program, DNL126, for Sanfilippo syndrome. These two programs are anticipated to develop into a profitable franchise of TransportVehicleTM (TV) enabled enzyme replacement therapies for the company. Denali Therapeutics, Inc. (NASDAQ:DNLI) is expanding its TV-enabled portfolio of therapeutic enzymes, oligonucleotides, and antibodies. It plans to advance 1-2 additional TV programs into the clinic each year for the next three years. This TV platform holds considerable potential to deliver a new class of barrier-crossing therapeutics, which is why analysts are optimistic about its operations. Overall, DNLI ranks 9th on our list of the 12 biotech stocks with the biggest upside potential. While we acknowledge the potential of biotech stocks, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DNLI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 20 Best AI Stock To Buy Now and 30 Most Important AI Stocks According to BlackRock . Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DNLI", "date": "2025-01-17T19:18:02", "sentiment": {"score": 0.24023280292749405, "confidence": 0.33208003640174866, "probabilities": {"positive": 0.33208003640174866, "negative": 0.09184723347425461, "neutral": 0.5760726928710938}}, "embedding": [-0.08302000164985657, -0.11240029335021973, -0.028054120019078255, -0.11578835546970367, -0.01698622852563858, -0.02206328883767128, -0.0563424676656723, 0.16576111316680908, 0.1259640008211136, 0.05109136924147606, -0.18778660893440247, 0.10453774034976959, -0.07472619414329529, 0.0600571408867836, -0.04857359454035759, -0.055230915546417236, -0.05738995224237442, 0.02192939817905426, -0.09134943783283234, 0.09497984498739243, -0.040134184062480927, -0.023707184940576553, 0.00040667084977030754, 0.055254947394132614, -0.003099285066127777, -0.010341905057430267, 0.010186981409788132, -0.04501572251319885, -0.22770056128501892, -0.03597644716501236, -0.03332412987947464, 0.17664265632629395, 0.08093395829200745, -0.10219345986843109, 0.036433473229408264, 0.11557978391647339, -0.06703098118305206, 0.1211443841457367, 0.10110723227262497, -0.0022073581349104643, 0.008494602516293526, -0.043270014226436615, -0.08778402209281921, 0.056528881192207336, 0.12098126113414764, -0.20371384918689728, -0.01499074324965477, -0.051334984600543976, 0.08117981255054474, -0.011746551841497421, -0.18228521943092346, -0.14922456443309784, 0.02394261211156845, 0.04409200698137283, -0.07599466294050217, 0.029339877888560295, -0.07093776017427444, -0.01687430962920189, 0.028133943676948547, 0.010168450884521008, 0.10190827399492264, -0.06534869968891144, 0.06341717392206192, -0.0034947767853736877, 0.10235422849655151, -0.061505720019340515, 0.06056557968258858, 0.08124859631061554, -0.06599472463130951, 0.031205542385578156, 0.11147661507129669, -0.10174651443958282, -0.11942727863788605, -0.05192768573760986, -0.0360533706843853, 0.06765793263912201, 0.12477804720401764, 0.22999271750450134, 0.21855595707893372, -0.15596166253089905, 0.20020198822021484, -0.012309504672884941, 0.02395148202776909, -0.019052155315876007, -0.11102155596017838, 0.040679559111595154, 0.09734372049570084, -0.0452042818069458, 0.06250384449958801, -0.004420854151248932, 0.01019526831805706, -0.05624351650476456, -0.010414102114737034, -0.02441045269370079, -0.037015195935964584, -0.011978071182966232, -0.12995809316635132, 0.09072685986757278, 0.09476511925458908, -0.018126172944903374, 0.12148799747228622, 0.02340254932641983, -0.15098929405212402, 0.020687662065029144, -0.07062289118766785, -0.09720113128423691, 0.0055223386734724045, -0.03546347841620445, 0.15145006775856018, 0.1589917242527008, -0.10038664191961288, 0.16530053317546844, -0.11242615431547165, 0.010322079062461853, -0.14422351121902466, 0.12305091321468353, -0.035632528364658356, -0.027702854946255684, 0.14317700266838074, -0.034906357526779175, -0.009465890936553478, 0.055508799850940704, -0.12887787818908691, -0.14328646659851074, -0.01103043183684349, 0.07564941048622131, -0.1987108588218689, 8.59678838627473e-33, 0.020151745527982712, 0.017025737091898918, 0.005608079023659229, -0.0021034181118011475, -0.04639342427253723, -0.05588121339678764, -0.024990670382976532, -0.030953308567404747, -0.14787185192108154, -0.09798327088356018, -0.22461846470832825, 0.0785723477602005, -0.06662245839834213, 0.027141470462083817, -0.05115480720996857, -0.14987051486968994, -0.05248526111245155, -0.01910426840186119, 0.056579116731882095, -0.03357243537902832, -0.14646688103675842, 0.07068564742803574, -0.09176581352949142, 0.05974149703979492, 0.022516006603837013, -0.07491664588451385, -0.12643776834011078, 0.04557685926556587, -0.0284243393689394, 0.04174577444791794, -0.02244729921221733, 0.04237644374370575, 0.0027523627504706383, -0.07188194990158081, 0.006413034629076719, -0.06093217805027962, -0.0165372546762228, -0.0698045939207077, 0.05593264847993851, 0.06936528533697128, -0.08011293411254883, 0.1645822525024414, -0.16717736423015594, -0.07954539358615875, 0.06935597956180573, 0.10885094106197357, -0.031772054731845856, 0.012584938667714596, -0.03483998775482178, -0.007193516008555889, -0.136176198720932, 0.08383230865001678, 0.10001865029335022, -0.06293614953756332, 0.054914481937885284, 0.003001804929226637, -0.15593647956848145, -0.11488297581672668, -0.0021319910883903503, 0.1681693196296692, -0.02703321911394596, 0.12068099528551102, 0.00748153030872345, 0.16221266984939575, -0.14766821265220642, 0.20003445446491241, 0.038368064910173416, 0.109142005443573, -0.05544457584619522, 0.16975048184394836, -0.054308243095874786, -0.04761455953121185, -0.012045526877045631, -0.03942166268825531, 0.013313576579093933, -0.06430506706237793, -0.03412288427352905, 0.08386215567588806, -0.0019819382578134537, 0.11788038164377213, 0.10984485596418381, 0.01485997810959816, -0.0626247301697731, 0.016382336616516113, -0.015211757272481918, -0.05194459110498428, 0.0542924702167511, 0.016864698380231857, 0.030577857047319412, 0.04175715893507004, -0.07101206481456757, -0.05378641188144684, 0.007820254191756248, 0.1817150115966797, 0.06701627373695374, -1.0899456923260816e-32, 0.0231911763548851, -0.05662528797984123, -0.03161509707570076, -0.03289337083697319, -0.0654887855052948, 0.02669021673500538, 0.07518184930086136, -0.12824329733848572, 0.07889958471059799, -0.06959851831197739, 0.04018999636173248, 0.0808994248509407, -0.05223800987005234, 0.042244747281074524, -0.15488511323928833, 0.005071130581200123, -0.07868547737598419, -0.05216643214225769, -0.05973632633686066, -0.025048408657312393, 0.047005247324705124, 0.14432115852832794, -0.18765787780284882, 0.04189588502049446, -0.02063385397195816, 0.10275180637836456, -0.0978425145149231, 0.141163632273674, 0.013305893167853355, -0.045170921832323074, -0.09305774420499802, -0.012151330709457397, -0.1906014382839203, 0.1356598436832428, -0.06401406973600388, 0.04023616388440132, 0.024876151233911514, -0.11651462316513062, 0.06277422606945038, -0.03023456409573555, 0.09754898399114609, 0.04630611464381218, -0.020524494349956512, 0.027513103559613228, 0.06842295080423355, -0.024042436853051186, -0.023254524916410446, 0.0617225356400013, 0.10964836180210114, 0.03331035003066063, -0.03772720694541931, 0.029131552204489708, 0.04037307947874069, 0.031013865023851395, -0.07679079473018646, 0.00798000954091549, 0.029738647863268852, 0.030990615487098694, -0.08090071380138397, 0.11514288187026978, 0.09588156640529633, 0.09627494215965271, 0.04221697151660919, 0.019965756684541702, -0.009476043283939362, 0.05659259110689163, 0.09408465027809143, -0.042359717190265656, -0.04564475268125534, -0.10271716117858887, 0.1018919125199318, -0.04878435283899307, -0.007306578569114208, -0.05154464393854141, -0.07675891369581223, 0.18271702527999878, -0.12054730206727982, -0.15112218260765076, -0.1761205494403839, 0.07607616484165192, 0.050495460629463196, 0.00892559252679348, -0.014941900037229061, 0.034176431596279144, -0.046142712235450745, 0.17246955633163452, -0.004281365312635899, -0.07293006777763367, -0.07451723515987396, -0.05950602516531944, -0.0725492537021637, -0.23301389813423157, -0.0709720104932785, 0.10438261926174164, -0.052117519080638885, -1.0069875600038358e-07, 0.11378650367259979, -0.14047914743423462, -0.03284049406647682, -0.11105601489543915, 0.04511095583438873, -0.10683414340019226, -0.014181723818182945, 0.025714129209518433, 0.17427918314933777, 0.24170857667922974, 0.07152559608221054, 0.16961105167865753, -0.18701833486557007, 0.09732653200626373, -0.032168660312891006, 0.05930262804031372, -0.15354284644126892, 0.0642506331205368, -0.0409935861825943, -0.03435901552438736, 0.004386376589536667, 0.0978025496006012, 0.01873891055583954, 0.010414807125926018, 0.10052000731229782, -0.12535443902015686, 0.08007235825061798, 0.02942134067416191, 0.026935473084449768, 0.031363338232040405, -0.010566267184913158, -0.0019959621131420135, 0.15456417202949524, 0.04055095463991165, -0.008787715807557106, -0.09025157988071442, 0.10227139294147491, 0.039023760706186295, -0.015920007601380348, 0.040065743029117584, -0.05082894116640091, -0.05715585872530937, -0.09515956044197083, -0.020172996446490288, -0.01083354651927948, -0.07827334105968475, -0.07226705551147461, 0.12215591967105865, 0.06930229067802429, -0.14835986495018005, 0.025316091254353523, 0.024963300675153732, 0.03223521634936333, -0.0009755883365869522, -0.03344963490962982, 0.08796396851539612, -0.1414024829864502, 0.026770886033773422, -0.07838624715805054, -0.052015624940395355, 0.0074958764016628265, -0.23421163856983185, 0.19332164525985718, 0.003681015223264694], "changes": {"1wk": 1.3223848798135547}}, {"text": "Denali Gains 26.6% in a Year: How Should You Play the Stock? Zacks Equity Research Tue, Jan 21, 2025, 2:13 PM 5 min read In This Article: DNLI -6.27% SNY -1.82% Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry\u2019s decline of 14.3%. The stock has also outperformed the sector and the S&P 500 Index in this time frame. Denali is developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative and lysosomal storage diseases.\u00a0 The upward price trajectory can be attributed to positive pipeline updates. DNLI Outperforms Industry, Sector & S&P 500 Zacks Investment Research Image Source: Zacks Investment Research DNLI\u2019s Pipeline Promise Potential Denali recently announced expected milestones for 2025 and its priorities to further advance its portfolio. The company\u2019s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome). Denali stated that it is on track to submit a biologics license application (BLA) for tividenofusp alfa for Hunter syndrome in early 2025 under the accelerated approval pathway. It is gearing up for a launch of tividenofusp alfa in the United States in late 2025 or early 2026. The FDA recently granted the Breakthrough Therapy Designation to the drug for this indication. DNLI is evaluating DNL126 for Sanfilippo syndrome type A (MPS IIIA). Preliminary data from the ongoing phase I/II study of DNL126 have demonstrated a substantial reduction in cerebrospinal fluid heparan sulfate (CSF HS) levels from baseline, including normalization. Denali will seek alignment with the FDA on a path for accelerated approval based on these encouraging results. The candidate has been selected for the FDA \u201cSupport for clinical Trials Advancing Rare disease Therapeutics\u201d (START) program, designed to accelerate the development of rare disease therapeutics. Denali and partner Biogen BIIB have collaborated to develop and commercialize small molecule inhibitors of LRRK2. Biogen is conducting the global phase IIb LUMA study, which is evaluating the ability of BIIB122 to slow disease progression as compared to placebo in approximately 640 participants with early-stage Parkinson's disease. Denali recently initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151) in LRRK2-associated Parkinson's disease with the aim to generate biomarker and safety data to inform how LRRK2 inhibition may impact this disease. Another candidate in DNLI\u2019s deep pipeline is TAK-594/DNL593, which is being evaluated for GRN-related frontotemporal dementia: Data from the ongoing phase I/II study of DNL593 have demonstrated dose-dependent increases in CSF progranulin levels, consistent with robust brain delivery of DNL593, in healthy volunteers. Dosing is ongoing. Story Continues Denali also has multiple early-stage clinical and preclinical programs in its pipeline. DNLI\u2019s Collaborations With Bigwigs: A Positive Denali has collaborated with Biogen for BIIB122/DNL151 in Parkinson\u2019s disease and with Takeda for TAK-594/DNL593 in FTD-GRN. It has equal commercial rights for both the candidates in the United States. DNLI is also entitled to receive royalty payments for SAR443122/DNL758. It is licensed to Sanofi SNY and under development for ulcerative colitis. The influx of cash, either as milestone or royalty payments, bodes well for Denali. Denali Therapeutics Inc. Price, Consensus and EPS Surprise Denali Therapeutics Inc. price-consensus-eps-surprise-chart | Denali Therapeutics Inc. Quote DNLI\u2019s Sound Cash Position Denali has a sound cash position, which ensures that the company will be able to fund its ongoing pipeline programs. Cash, cash equivalents, and marketable securities totaled approximately $1.28 billion as of Sept. 30, 2024. Denali anticipates its cash runway to extend into 2028. Recent Pipeline Setbacks: A Concern for DNLI Though Denali has made encouraging pipeline progress, there have been a few setbacks. The company recently announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform trial is evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS). Results showed that the study did not meet the primary endpoint of efficacy in slowing disease progression as compared to placebo. The primary endpoint was evaluated as a change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) and survival through week 24. Key secondary endpoints, measuring muscle strength and respiratory function, were also not statistically different between the active and placebo groups at week 24. Denali and partner Sanofi were co-developing SAR443820/DNL788. However, Sanofi informed Denali that the K2 phase II study evaluating the safety and efficacy of oditrasertib (SAR443820/DNL788) on serum neurofilament light chain levels in participants with multiple sclerosis was discontinued. The decision was taken after the study did not meet the primary and key secondary endpoints. We remind investors that Sanofi had earlier discontinued the development of SAR443820/DNL788 for the treatment of ALS, based on the results of the phase II HIMALAYA study, which did not meet the primary endpoint. Conclusion Large biotech companies are considered safe havens for investors interested in this sector. A potential approval of tividenofusp alfa should be a significant boost for DNLI. The company\u2019s sound cash position is a positive and ensures DNLI\u2019s ability to fund ongoing programs. However, pipeline setbacks are a cause of concern. Investors should also wait for the successful commercialization of tividenofusp alfa upon a potential approval. Denali currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DNLI", "date": "2025-01-21T14:13:00", "sentiment": {"score": 0.9037885973230004, "confidence": 0.9151437878608704, "probabilities": {"positive": 0.9151437878608704, "negative": 0.01135519053786993, "neutral": 0.07350098341703415}}, "embedding": [-0.17437060177326202, -0.22341305017471313, -0.05492374300956726, -0.1436229646205902, -0.12703923881053925, -0.06929777562618256, -0.09762890636920929, 0.2675643563270569, 0.028191860765218735, 0.010114030912518501, -0.065068818628788, 0.11080276966094971, -0.08445268869400024, 0.10413742065429688, -0.06255963444709778, 0.05890769511461258, -0.0191732756793499, 0.015035299584269524, -0.08415325731039047, 0.015096715651452541, 0.01449897512793541, -0.040928710252046585, -0.09257589280605316, 0.03380347043275833, -0.0308176651597023, 0.03807120770215988, -0.06701149046421051, -0.006335099693387747, -0.11452779918909073, -0.0008610780350863934, 0.01759021356701851, 0.11234918981790543, -0.03868608549237251, -0.14116603136062622, 0.1018427386879921, 0.04689255729317665, -0.14416152238845825, 0.006752250716090202, -0.07150586694478989, -0.1270516961812973, 0.038480859249830246, -0.06676271557807922, -0.12048391997814178, 0.016986289992928505, 0.05411162227392197, -0.18022800981998444, -0.1292300522327423, 0.11322394013404846, 0.04088463634252548, -0.00042638182640075684, -0.168043315410614, -0.1502419412136078, 0.07694539427757263, 0.11990101635456085, -0.06336593627929688, -0.025032011792063713, -0.10776214301586151, 0.03124922327697277, -0.016267238184809685, 0.026935836300253868, -0.036683589220047, -0.0454089380800724, 0.05963591858744621, -0.049117930233478546, 0.11296926438808441, 0.05164559185504913, 0.027493804693222046, -0.06868252158164978, 0.02967565506696701, -0.0025144428946077824, 0.03260207176208496, -0.03477172926068306, -0.01880062185227871, 0.12233009189367294, -0.0384591743350029, 0.04301568493247032, 0.15619629621505737, 0.11096209287643433, 0.20268723368644714, -0.26108309626579285, 0.1154949888586998, 0.12516701221466064, 0.09074506163597107, 0.05119936168193817, 0.04342367872595787, 0.08591483533382416, -0.033577509224414825, 0.12124495208263397, 0.04946491867303848, 0.0004733167588710785, 0.06864072382450104, -0.04434676840901375, -0.06230812892317772, -0.055114321410655975, -0.03517376258969307, 0.011598764918744564, -0.08617955446243286, 0.05068520829081535, -0.013796964660286903, -0.014874309301376343, 0.04872875660657883, 0.04680038243532181, -0.07179034501314163, -0.10541481524705887, -0.03135189786553383, -0.04257785901427269, 0.11895917356014252, 0.0211205892264843, 0.04815301299095154, 0.024170173332095146, 0.019524317234754562, 0.059701696038246155, 0.08563357591629028, 0.02052917331457138, -0.09465889632701874, 0.25246232748031616, -0.036015454679727554, 0.03616974502801895, 0.1960395872592926, -0.002647051587700844, 0.02433374710381031, -0.002734589157626033, 0.016903484240174294, -0.1469118893146515, 0.08035872876644135, 0.08362124860286713, -0.16478420794010162, 1.0492254659876437e-32, 0.05785861238837242, -0.008167576976120472, -0.05866391211748123, 0.06155475974082947, -0.046692587435245514, -0.09979696571826935, 0.04722527414560318, 0.05414237827062607, -0.11036569625139236, -0.154458150267601, -0.19177421927452087, -0.038440853357315063, -0.06731344759464264, 0.10907673090696335, -0.09686075150966644, -0.10622820258140564, 0.05924638360738754, 0.0679653137922287, -0.005928482860326767, -0.0641428530216217, 0.08480078727006912, -0.062128689140081406, -0.06297310441732407, -0.055829986929893494, 0.04447714239358902, 0.049543291330337524, -0.0935574322938919, 0.11405391991138458, 0.10839278250932693, 0.09373975545167923, -0.12206493318080902, -0.01722392812371254, 0.05997946858406067, -0.05924621969461441, -0.06197897344827652, -0.07035482674837112, -0.08023328334093094, -0.1091112345457077, 0.10314275324344635, 0.11006905138492584, 0.052570585161447525, 0.11435630917549133, -0.1258833408355713, -0.054726701229810715, 0.032695088535547256, -0.06082969903945923, -0.015596442855894566, 0.0034577175974845886, -0.009026307612657547, -0.051757946610450745, 0.01488560438156128, 0.00653443019837141, 0.027964243665337563, -0.13417120277881622, -0.03374691307544708, -0.016209246590733528, -0.07880356162786484, -0.11839677393436432, 0.0745009034872055, 0.13783910870552063, 0.022672664374113083, 0.10542427003383636, -0.06692452728748322, 0.05026453733444214, 0.03682127594947815, 0.040633540600538254, 0.05422569811344147, 0.01813448965549469, -0.0852915421128273, 0.009979484602808952, -0.03657787665724754, -0.09350930154323578, 0.12759089469909668, 0.01941998302936554, 0.1296013444662094, -0.0962226539850235, 0.10915862023830414, 0.15335500240325928, 0.0076384893618524075, -0.03971902281045914, -0.05636097490787506, 0.06213943660259247, -0.08390455693006516, 0.09696908295154572, 0.025384927168488503, 0.015823371708393097, 0.03962133824825287, 0.05575735121965408, -0.19608476758003235, -0.14195355772972107, 0.06296294927597046, -0.07139389961957932, -0.01650562509894371, 0.10508522391319275, 0.04795427620410919, -1.1324608250698282e-32, -0.11190354079008102, 0.059758175164461136, -0.04178862273693085, -0.08512218296527863, -0.04639548808336258, 0.10132502019405365, 0.0674193948507309, -0.07728348672389984, 0.21625468134880066, -0.0502874031662941, 0.062102362513542175, 0.07542707026004791, -0.003139857668429613, -0.07562556117773056, -0.10065421462059021, 0.07081420719623566, -0.14053049683570862, -0.07420967519283295, -0.05597205460071564, -0.022538237273693085, 0.13933753967285156, 0.20728793740272522, -0.06981226056814194, 0.13947933912277222, 0.046012721955776215, 0.010334457270801067, 0.07186302542686462, 0.13321638107299805, 0.023388495668768883, -0.03570692241191864, -0.05837487801909447, -0.002705192659050226, -0.2290373295545578, -0.0589924231171608, -0.048143453896045685, -0.022266119718551636, 0.006195363588631153, -0.2488798201084137, -0.12642142176628113, -0.03641363978385925, 0.04333677887916565, 0.02753913775086403, 0.01921146735548973, 0.058943167328834534, 0.04936052858829498, 0.04616541042923927, 0.11129914224147797, -0.07045494019985199, 0.13706712424755096, 0.007995061576366425, -0.022465724498033524, -0.013692779466509819, 0.025810154154896736, 0.13256141543388367, -0.08057273179292679, -0.019708050414919853, 0.10665035992860794, 0.03930036351084709, -0.22989808022975922, 0.018533360213041306, -0.01378741767257452, 0.06516781449317932, -0.008274595253169537, -0.05514732748270035, 0.09576477855443954, 0.12815558910369873, 0.07986965775489807, -0.05453198030591011, 0.08448445796966553, -0.15438780188560486, -0.031793199479579926, -0.08454382419586182, -0.03400897979736328, -0.0795215368270874, -0.10373073816299438, -0.0129045145586133, -0.025176431983709335, -0.06345104426145554, -0.02388688176870346, -0.07807525247335434, -0.01885092258453369, -0.017198707908391953, -0.017167869955301285, 0.07134314626455307, 0.1463087499141693, 0.03744237869977951, 0.009000761434435844, -0.03212181478738785, -0.014756632968783379, 0.08846970647573471, -0.10226978361606598, -0.09059083461761475, -0.11068906635046005, 0.11397510766983032, -0.015693016350269318, -1.0050015220031128e-07, 0.16596734523773193, 0.011462030932307243, -0.07352781295776367, -0.03830882906913757, 0.03088654950261116, -0.0973585993051529, -0.10679514706134796, 0.08613255620002747, 0.02835785411298275, 0.19061273336410522, -0.002616647630929947, 0.1543860137462616, -0.08257965743541718, -0.07918316125869751, -0.05904656648635864, 0.042098041623830795, 0.03254145756363869, 0.09093886613845825, -0.1281944066286087, -0.05553546920418739, 0.055449798703193665, -0.05282551422715187, 0.029678285121917725, -0.013116633519530296, 0.08091477304697037, -0.15003493428230286, 0.07836427539587021, 0.020471757277846336, 0.07278753072023392, -0.062280718237161636, -0.04713732749223709, 0.038225580006837845, 0.11613757908344269, 0.07517635822296143, 0.02805429697036743, -0.0933360755443573, 0.0714535266160965, 0.12054748833179474, 0.048191312700510025, 0.16598276793956757, 0.08042542636394501, -0.041422225534915924, -0.010264180600643158, -0.0036301948130130768, -0.004113118629902601, -0.04270346462726593, -0.13172230124473572, -0.007350652478635311, 0.0739455372095108, -0.027640212327241898, -0.00020907609723508358, -0.03379177302122116, 0.010208395309746265, -0.009651973843574524, -0.07226204127073288, 0.11538136750459671, -0.14496035873889923, 0.008178823627531528, -0.01381966844201088, 0.020124614238739014, 0.0998501181602478, -0.0659528523683548, 0.13176248967647552, 0.016298025846481323], "changes": {"1wk": 0.6510399851120848}}, {"text": "Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases Denali Therapeutics Inc. Mon, Jan 13, 2025, 4:00 PM 10 min read In This Article: DNLI -6.27% Denali Therapeutics Inc. FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in early 2025 Preparing for commercial launch of tividenofusp alfa for Hunter syndrome in late 2025 or early 2026 Enable accelerated approval pathway for DNL126 for Sanfilippo syndrome Type A (MPS IIIA) Expand and advance portfolio of multiple TransportVehicle TM (TV) enabled programs for delivery of enzyme, oligonucleotide, and antibody therapeutics for rare and common diseases SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced key anticipated milestones for 2025 across its portfolio. Chief Executive Officer, Ryan Watts, Ph.D., will highlight these priorities during a corporate presentation at the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 11:15 a.m. PDT. \"In 2025, we are on track to submit our first BLA for tividenofusp alfa for Hunter syndrome and prepare for commercial launch. In addition, we will seek alignment with the FDA on an accelerated approval path for our second program DNL126 for Sanfilippo syndrome. Together, we expect these two programs to be the foundation of a broad franchise of TransportVehicle TM (TV) enabled enzyme replacement therapies,\" said Ryan Watts, Ph.D., Chief Executive Officer of Denali. \"Further, we are expanding our TV-enabled portfolio of therapeutic enzymes, oligonucleotides, and antibodies, and plan to advance one to two additional TV programs into the clinic each year for the next three years. We are excited about the validation and broad potential of the TV platform to deliver a new class of barrier-crossing therapeutics with great potential for people living with rare and common diseases that impact the brain.\" 2025 Outlook Denali Therapeutics has pioneered and is delivering a new class of therapeutics using its TransportVehicle TM (TV) platform to enable and transform treatment for people living with rare and common diseases that impact the brain. The TV platform is designed to deliver large molecules \u2013 enzymes (ETV), oligonucleotides (OTV), and antibodies (ATV) \u2013 across biological barriers including the blood-brain barrier, enabling broad biodistribution into targeted tissues where treatment is needed. Expected progress and key milestones in 2025 across Denali\u2019s portfolio of TV-enabled and small molecule programs are summarized below. CLINICAL PROGRAMS Tividenofusp alfa (DNL310, ETV:IDS) for Hunter syndrome (MPS II): On January 7, 2025, the FDA granted tividenofusp alfa Breakthrough Therapy Designation for Hunter syndrome (MPS II). Denali expects to submit a biologics license agreement (BLA) under the accelerated approval pathway in early 2025 and is preparing for the U.S. launch of tividenofusp alfa for the treatment of Hunter syndrome in late 2025 or early 2026. Denali is engaged in prelaunch activities including continued dialogue with prescribers and payers, building a suite of patient support services and capabilities to enable broad access, and building a right-sized team in commercial and medical affairs to support tividenofusp alfa and additional Enzyme TV (ETV) launches. The ongoing open-label extension of the Phase 1/2 study will generate long-term safety data, and the ongoing global Phase 2/3 COMPASS study will support global approval. Target enrollment of neuronopathic participants in Cohort A of the COMPASS study has been completed. In addition to Breakthrough Therapy Designation, the FDA previously granted tividenofusp alfa Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for development in the treatment of MPS II. Additional Phase 1/2 results have been accepted for oral presentation at the 2025 WORLD Symposium conference taking place February 3-7, 2025. Story Continues DNL126 (ETV:SGSH) for Sanfilippo syndrome Type A (MPS IIIA) : Preliminary data from the ongoing Phase 1/2 study of DNL126 have demonstrated a substantial reduction in cerebrospinal fluid heparan sulfate (CSF HS) levels from baseline, including normalization. Based on these results, Denali will seek alignment with the FDA on a path for accelerated approval. DNL126 has Orphan Disease designation, Fast Track status, and has been selected for the FDA \u201cSupport for clinical Trials Advancing Rare disease Therapeutics\u201d (START) program, designed to accelerate the development of rare disease therapeutics. TAK-594/DNL593 (PTV :PGRN) for GRN-related frontotemporal dementia: Data from the ongoing Phase 1/2 study of DNL593 have demonstrated dose-dependent increases in CSF progranulin levels, consistent with robust brain delivery of DNL593, in healthy volunteers. Dosing granulin (GRN)-related frontotemporal dementia (FTD-GRN) participants is ongoing. BIIB122/DNL151 ( small molecule LRRK2 inhibitor) for the treatment of Parkinson\u2019s disease (PD) : Denali and Biogen have a strategic collaboration to jointly develop and commercialize small molecule inhibitors of LRRK2. Biogen is conducting the global Phase 2b LUMA study, which is evaluating the ability of BIIB122 to slow disease progression as compared to placebo in approximately 640 participants with early-stage Parkinson's disease; completion of enrollment is expected in 2025. In addition, Denali is conducting the complementary Phase 2a BEACON study in LRRK2-associated Parkinson's disease with the aim to generate biomarker and safety data to inform how LRRK2 inhibition may impact this disease. DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS): Following previously reported topline results that the primary endpoint was not met in the HEALEY ALS platform trial ( press release ), further analyses are anticipated later in 2025, including neurofilament light (NfL) and other fluid biomarkers, data from pre-specified subgroups, as well as extended findings from the active treatment extension period. IND-ENABLING STAGE PROGRAMS Beginning in 2025, Denali expects to advance one to two additional programs to the clinic per year over the next three years across its TV-enabled franchises (ETV, OTV, and ATV). IND-enabling stage programs include: ETV DNL952 (ETV:GAA) for Pompe disease DNL111 (ETV:Gcase) for Parkinson\u2019s disease and Gaucher disease DNL622 (ETV:IDUA) for Hurler syndrome (MPS I) OTV DNL628 (OTV:MAPT) targeting tau for Alzheimer\u2019s disease DNL422 (OTV:SNCA) targeting alpha synuclein for Parkinson\u2019s disease ATV DNL921 (ATV:Abeta) targeting amyloid beta for Alzheimer\u2019s disease Multiple ATV-enabled oncology programs PARTNERSHIPS Denali has active collaborations with Biogen for BIIB122/DNL151 in Parkinson\u2019s disease and with Takeda for TAK-594/DNL593 in FTD-GRN, both with 50/50 U.S. commercial rights. Denali also stands to receive royalty payments for SAR443122/DNL758, which is licensed to Sanofi and in development for ulcerative colitis. FINANCIAL OUTLOOK Cash, cash equivalents, and marketable securities were approximately $1.28 billion as of September 30, 2024. Denali anticipates its cash runway will extend into 2028. UPCOMING INVESTOR CONFERENCES Oppenheimer's 35th Annual Healthcare Life Sciences Conference, February 11-12 Leerink Partners Global Healthcare Conference, March 9-12 Jefferies Biotech on the Beach, March 11-12 UBS Virtual CNS Day 2025, March 17 Stifel CNS Days 2025, March 18-19 Webcast details for Denali\u2019s presentation at the 43 rd annual J.P. Morgan Healthcare Conference A live and archived webcast of the Denali presentation during the J.P. Morgan Conference on Tuesday, Jan. 14, at 11:15 a.m. PDT will be available on the Events page under the Investor section of the Denali website at https://investors.denalitherapeutics.com/events . About Denali Therapeutics Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding the future results of operations and financial position of Denali Therapeutics Inc. (\u201cDenali\u201d or the \u201cCompany\u201d); Denali\u2019s business strategy and business plans, including expected key milestones for Denali's therapeutic portfolio in 2025 and beyond and Denali\u2019s ability to execute on its tailored commercial strategies; plans, timelines, expectations related to Denali's TransportVehicle TM (TV) platform and its therapeutic and commercial potential; plans, timelines, and expectations relating to DNL310, including enrollment in ongoing clinical studies, the timing and availability of data in the Phase 1/2 study and Phase 2/3 COMPASS study, the timing of planned regulatory filings, and the timing, likelihood, and scope of regulatory approvals and commercial launch; plans, timelines, and expectations related to DNL126, including the timing and availability of data from the Phase 1/2 study, interactions with the FDA, and the timing, likelihood, and scope of regulatory approval; plans and expectations regarding DNL593, including the ongoing the Phase 1/2 study; plans, timelines, and expectations related to DNL151, including the ongoing Phase 2a BEACON study and the Phase 2b LUMA study; plans, timelines, and expectations related to DNL343, including the timing and availability of data and further analysis related to Phase 2/3 HEALEY Platform Trial; expectations regarding Denali's preclinical studies and the timing and likelihood of advancement of additional programs to clinical studies; Denali's third-party collaborations and potential royalties; Denali's anticipated operating expenses and cash runway; and statements made by Denali\u2019s Chief Executive Officer. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: Denali\u2019s dependence on successful development of its BBB platform technology and TV-enabled product candidates; Denali\u2019s ability to initiate and enroll patients in its current and future clinical trials; Denali\u2019s ability to conduct or complete clinical trials on expected timelines; Denali\u2019s reliance on third parties for the manufacture and supply of its product candidates for clinical trials; the potential for clinical trial results to differ from preclinical, early clinical, preliminary or expected results; the risk of significant adverse events, toxicities, or other undesirable side effects; the risk that results from early clinical biomarker studies will not translate to clinical benefit in late clinical studies; the risk that product candidates may not receive regulatory approval necessary to be commercialized; developments relating to Denali\u2019s competitors and its industry, including competing product candidates and therapies; Denali\u2019s ability to obtain, maintain, or protect intellectual property rights; and other risks and uncertainties. In light of these risks, uncertainties, and assumptions, the forward-looking statements in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Denali's product candidates are investigational, and their safety and efficacy profiles have not yet been established. No Denali product candidates have been approved by any health authority for any use. Information regarding additional risks and uncertainties may be found in Denali\u2019s Annual and Quarterly Reports filed on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 28, 2024, and November 6, 2024, respectively, and Denali\u2019s future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali\u2019s expectations, except as required by law. Investor Contact: Laura Hansen, Ph.D. Vice President, Investor Relations (650) 452-2747 hansen@dnli.com Media Contact Rich Allan FGS Global (503) 851-0807 rich.allan@fgsglobal.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DNLI", "date": "2025-01-13T16:00:00", "sentiment": {"score": 0.6104829339310527, "confidence": 0.6203625202178955, "probabilities": {"positive": 0.6203625202178955, "negative": 0.009879586286842823, "neutral": 0.36975789070129395}}, "embedding": [-0.17826884984970093, -0.2341347634792328, 0.0053258053958415985, -0.1298193335533142, -0.10878483951091766, -0.0823625773191452, -0.10649167001247406, 0.18995968997478485, 0.020503602921962738, 0.04258478060364723, -0.096882164478302, 0.08753880858421326, -0.1220821812748909, 0.13154569268226624, -0.0072979433462023735, 0.06756739318370819, 0.023909352719783783, -0.060958944261074066, -0.050517816096544266, 0.052664924412965775, -0.024177180603146553, 0.010576550848782063, -0.053201254457235336, 0.03022558055818081, -0.1029926985502243, -0.028001053258776665, -0.14468468725681305, 0.004157467745244503, -0.12925052642822266, -0.06523909419775009, -0.012813960202038288, 0.12396712601184845, -0.04774463176727295, -0.12102852761745453, 0.019878970459103584, 0.02376813068985939, -0.15319055318832397, -0.0034495615400373936, -0.05957074463367462, -0.1267508864402771, 0.03085123375058174, -0.07484722882509232, -0.1287718564271927, 0.06975752115249634, 0.017118001356720924, -0.23391515016555786, -0.14100921154022217, 0.05953753739595413, 0.008814333006739616, 0.07014209032058716, -0.14757871627807617, -0.21998170018196106, 0.04676828533411026, 0.09299233555793762, -0.09034742414951324, -0.010035696439445019, -0.09148190915584564, -0.0038605774752795696, -0.05163313448429108, 0.015477188862860203, -0.020358586683869362, -0.06797201186418533, -0.031628914177417755, 0.05449347943067551, 0.16771113872528076, 0.057285651564598083, 0.07728414237499237, -0.0009827008470892906, 0.03250424936413765, -0.005557999946177006, 0.01592542789876461, -0.05421978235244751, -0.030208375304937363, 0.10031640529632568, -0.00987997092306614, 0.06316424906253815, 0.16522261500358582, 0.15955868363380432, 0.24010148644447327, -0.20656660199165344, 0.1457381397485733, 0.16118454933166504, 0.015537861734628677, 0.008776131086051464, 0.01656268537044525, 0.08607062697410583, -0.07919001579284668, 0.12315066903829575, -0.017019333317875862, -0.00925382785499096, 0.03842310979962349, -0.09488096833229065, 0.05556874722242355, -0.04842042922973633, -0.0675014778971672, 0.03946992754936218, -0.08500897884368896, -0.011789805255830288, 0.01818879321217537, 0.006492721848189831, -0.006692909635603428, 0.04161395505070686, -0.09159068763256073, -0.07449999451637268, -0.06155751273036003, -0.0676441565155983, 0.06190448999404907, -0.009791092947125435, 0.03821355104446411, 0.014331570826470852, -0.0004563780967146158, 0.10919220000505447, 0.15489265322685242, 0.059657007455825806, -0.09487663954496384, 0.28374046087265015, -0.12299484759569168, 0.012231900356709957, 0.2861896753311157, -0.002597150392830372, 0.07594060152769089, -0.021292779594659805, 0.06580331921577454, -0.16519281268119812, 0.07587305456399918, 0.07943691313266754, -0.12922802567481995, 9.823847266163775e-33, 0.013689776882529259, 0.031450919806957245, -0.04340079799294472, 0.12830835580825806, 0.027814097702503204, -0.07476769387722015, 0.013781975954771042, 0.056116294115781784, -0.22190549969673157, -0.10170275717973709, -0.16969889402389526, -0.03255084156990051, 0.007282343693077564, 0.18679121136665344, -0.10737956315279007, -0.09585703909397125, 0.0004999227821826935, 0.10544705390930176, -0.024829842150211334, -0.00762087432667613, 0.11508631706237793, -0.010898072272539139, -0.09232872724533081, -0.033509548753499985, 0.045409124344587326, 0.12902149558067322, -0.1178460419178009, 0.07653170824050903, 0.10533593595027924, 0.09206927567720413, -0.18281644582748413, 0.01018676720559597, -0.024479079991579056, -0.037275489419698715, -0.01538713276386261, -0.06762248277664185, -0.10805363208055496, -0.18698132038116455, 0.056538619101047516, 0.05961408093571663, 0.0994587391614914, 0.12680190801620483, -0.16806070506572723, 0.004068991634994745, 0.05301269143819809, -0.07763375341892242, 0.035637978464365005, -0.05403819680213928, -0.01597852259874344, -0.08509591221809387, 0.06966038048267365, 0.00877518393099308, 0.0024605565704405308, -0.18500494956970215, 0.013553770259022713, 0.010927632451057434, -0.08779394626617432, -0.0928211659193039, 0.04458538070321083, 0.12178515642881393, 0.09094075858592987, 0.09454427659511566, -0.030964750796556473, 0.024899283424019814, 0.007794603705406189, -0.005388645455241203, 0.006880216300487518, -0.021806178614497185, -0.04678226262331009, -0.000556205864995718, -0.003290693275630474, -0.07589924335479736, 0.09842023998498917, -0.026317669078707695, 0.15139472484588623, -0.02988140843808651, 0.15520288050174713, 0.08828075230121613, 0.012243916280567646, -0.014183193445205688, -0.0976625606417656, 0.03640402853488922, -0.06526919454336166, 0.09885511547327042, 0.06519303470849991, -0.10069850087165833, 0.08351579308509827, -0.007308214902877808, -0.20579269528388977, -0.1480787694454193, 0.1483759731054306, -0.035310663282871246, -0.008539926260709763, 0.09962758421897888, 0.03327319771051407, -1.1611400954308088e-32, -0.08113443851470947, 0.03969478979706764, -0.003169102594256401, -0.17248645424842834, -0.11328093707561493, 0.03628778085112572, 0.032581254839897156, -0.14542630314826965, 0.21027544140815735, -0.06915564835071564, 0.04546676203608513, 0.017428083345294, 0.008865702897310257, -0.11513824760913849, -0.11344298720359802, 0.010400887578725815, -0.09178781509399414, -0.09548982232809067, -0.09803043305873871, -0.028261112049221992, 0.1494341939687729, 0.24180720746517181, -0.1111668199300766, 0.07169988751411438, 0.10327134281396866, 0.022671259939670563, 0.14381572604179382, 0.13762395083904266, 0.0511268749833107, -0.1013660579919815, -0.06917741149663925, -0.07159347832202911, -0.22140683233737946, -0.03977515920996666, 0.021106550469994545, 0.06704942137002945, 0.09211726486682892, -0.23389074206352234, -0.07519780099391937, -0.0717460960149765, 0.05645197629928589, 0.008057004772126675, -0.07856698334217072, 0.058380965143442154, 0.0422823466360569, 0.04648170247673988, 0.016617529094219208, 0.022754836827516556, 0.15958093106746674, 0.022386465221643448, -0.017673596739768982, -0.0303889662027359, -0.028879614546895027, 0.05826491117477417, -0.08786293864250183, -0.009182386100292206, 0.09642939269542694, -0.026985742151737213, -0.11953028291463852, -0.023042431101202965, 0.013881072402000427, 0.06450723111629486, 0.029696617275476456, -0.0026319604367017746, 0.09099962562322617, 0.10528963059186935, 0.09397684037685394, -0.03158427029848099, -0.0200057290494442, -0.09727892279624939, -0.11200273036956787, -0.03699234873056412, -0.14367100596427917, -0.12056812644004822, -0.04512079805135727, 0.008703168481588364, -0.010999934747815132, -0.12358181923627853, 0.007045496720820665, -0.09854038059711456, -0.11353153735399246, -0.06785310804843903, -0.03268788382411003, 0.1248854398727417, 0.22680673003196716, 0.013255912810564041, 0.04514000564813614, -0.01766437292098999, 0.069036103785038, 0.09087453037500381, -0.07562407851219177, -0.11561557650566101, -0.0903303325176239, 0.13556063175201416, 0.02614959329366684, -1.0151644147526895e-07, 0.2837684154510498, 0.03616885840892792, -0.14478972554206848, -0.04111658036708832, 0.02635657787322998, -0.030942857265472412, -0.20733389258384705, 0.014355551451444626, 0.027833212167024612, 0.2165035903453827, 0.0022256290540099144, 0.2240637242794037, -0.11143961548805237, -0.0363926962018013, 0.024195149540901184, 0.06399933993816376, -0.03085874393582344, 0.08058994263410568, -0.16926002502441406, -0.0806271955370903, -0.0053497375920414925, 0.006764871068298817, 0.007424279116094112, -0.009398884139955044, 0.08762301504611969, -0.17137843370437622, 0.07817944884300232, 0.037541236728429794, 0.16495786607265472, -0.09473732113838196, -0.07402189075946808, 0.025046832859516144, 0.002144533209502697, 0.07096478343009949, 0.02446351945400238, -0.12245410680770874, 0.049167752265930176, 0.15861889719963074, 0.08372997492551804, 0.19393813610076904, 0.07034662365913391, -0.07306589931249619, -0.046408288180828094, 0.03217114880681038, -0.07603667676448822, -0.08767916262149811, -0.15807852149009705, -0.003812739159911871, 0.06677331030368805, -0.01081622950732708, -0.015992537140846252, -0.06571298837661743, 0.03007730469107628, 0.016698213294148445, -0.010503118857741356, 0.17048224806785583, -0.08049456030130386, -0.057579755783081055, 0.06370288133621216, 0.029049869626760483, 0.09269221127033234, 0.012323134578764439, 0.14473141729831696, -0.0004364084452390671], "changes": {"1wk": 11.944870517414317}}, {"text": "DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation Zacks Equity Research Thu, Jan 9, 2025, 7:20 PM 4 min read In This Article: DNLI -6.27% Denali Therapeutics Inc . DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter syndrome (MPS II). Denali\u2019s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome). Shares of DNLI have lost 1.9% in the past six months compared with the industry\u2019s 8.3% decline. Zacks Investment Research Image Source: Zacks Investment Research More on DNLI\u2019s Tividenofusp Alfa The FDA's above-mentioned designation is intended to expedite the development and review of therapeutic drugs being evaluated for the treatment of serious or life-threatening conditions. Breakthrough Therapy Designation is generally granted to a drug when evidences suggest that the investigational drug may provide substantial improvement over available therapy on at least one clinically significant endpoint. Data from the open-label phase I/II study have shown promising results, with positive effects on evidence-based surrogate endpoints and early signs of improved clinical outcomes in participants with Hunter syndrome. This designation will provide Denali with more intensive FDA guidance, including involvement of senior reviewers, and eligibility for rolling and priority review of the marketing application. In 2021, the FDA granted Fast Track designation to tividenofusp alfa for the treatment of patients with Hunter syndrome. In 2022, the European Medicines Agency granted Priority Medicines designation to tividenofusp alfa the. In September 2024, Denali announced the outcome of a successful meeting with the FDA, providing a path to filing a biologics license application (BLA) for tividenofusp alfa for accelerated approval and subsequent conversion to full approval for the treatment of Hunter syndrome. Denali expects to submit a BLA for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway. DNLI\u2019s Recent Pipeline Updates Denali recently initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor, is being evaluated in participants with LRRK2-associated Parkinson\u2019s disease (LRRK2-PD). The phase IIa study will evaluate safety and biomarkers associated with oral daily dosing of BIIB122 in approximately 50 participants with Parkinson\u2019s disease and LRRK2 pathogenic mutations confirmed by genetic testing. BIIB122 is also being evaluated in the ongoing global phase IIb LUMA study in participants with early-stage Parkinson\u2019s disease with or without an LRRK2 mutation in collaboration with Biogen BIIB. Story Continues The LUMA study is being conducted by Biogen. This study is expected to enroll approximately 640 participants with early-stage Parkinson\u2019s disease, including eligible ones with LRRK2 mutations. However, Denali recently announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform trial is evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS). Results showed that the study did not meet the primary endpoint of efficacy in slowing disease progression as compared with placebo. The primary endpoint was evaluated as a change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) and survival through week 24. Key secondary endpoints, measuring muscle strength and respiratory function, were also not statistically different between the active and placebo groups at week 24. Denali Therapeutics Inc. Price, Consensus and EPS Surprise Denali Therapeutics Inc. Price, Consensus and EPS Surprise Denali Therapeutics Inc. price-consensus-eps-surprise-chart | Denali Therapeutics Inc. Quote Earlier, partner Sanofi SNY discontinued the development of SAR443820/DNL788 for the treatment of ALS, based on the results of the phase II HIMALAYA study, which did not meet the primary endpoint. Denali and partner SNY were co-developing SAR443820/DNL788 for other indications. However, Sanofi informed Denali that the phase II study evaluating the safety and efficacy of SAR443820/DNL788 on serum neurofilament light chain levels in participants with multiple sclerosis was discontinued. The decision was taken after the study did not meet the primary and key secondary endpoints. DNLI's Zacks Rank and Stock to Consider Denali currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Halozyme Therapeutics HALO, which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 90 days, estimates for Halozyme Therapeutics\u2019 2024 earnings per share have improved from $3.95 to $4.07. Estimates for 2025 earnings per share have increased from $4.73 to $4.81 during the same timeframe. HALO\u2019s earnings beat estimates in three of the trailing four quarters and met once, delivering an average surprise of 14.86%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DNLI", "date": "2025-01-09T19:20:00", "sentiment": {"score": 0.7081593498587608, "confidence": 0.7601132988929749, "probabilities": {"positive": 0.7601132988929749, "negative": 0.05195394903421402, "neutral": 0.18793272972106934}}, "embedding": [-0.11885874718427658, -0.15113526582717896, 0.040379345417022705, -0.07904477417469025, -0.11629650741815567, -0.11123474687337875, -0.15665224194526672, 0.34019964933395386, 0.031996194273233414, 0.025664491578936577, -0.05726676434278488, 0.1235819011926651, -0.08996446430683136, 0.17567700147628784, -0.03109719604253769, 0.08324824273586273, 0.11610035598278046, 0.04536856710910797, -0.09449103474617004, -0.007394399493932724, -0.008623845875263214, 0.006697821896523237, -0.012743625789880753, 0.007701139897108078, -0.05807895213365555, -0.010355486534535885, -0.13892018795013428, -0.008834202773869038, -0.07545826584100723, 0.01156440656632185, 0.01636246219277382, 0.17180806398391724, -0.0014998354017734528, -0.14010994136333466, -0.0016336124390363693, -0.012691240757703781, -0.13199713826179504, 0.05433041229844093, -0.10493774712085724, -0.07057570666074753, 0.06335815787315369, -0.055956024676561356, -0.10932502150535583, 0.011554145254194736, -0.023511730134487152, -0.23953211307525635, -0.1297905147075653, 0.14162226021289825, -0.032929010689258575, 0.09439989924430847, -0.12216584384441376, -0.2204996943473816, 0.05072101578116417, 0.10796643048524857, -0.03329756110906601, -0.07143384218215942, -0.048069752752780914, 0.02568201534450054, -0.011367819271981716, 0.039016131311655045, -0.016682669520378113, 0.007977716624736786, -0.0496366061270237, -0.01958448439836502, 0.1537826657295227, 0.11141934990882874, 0.03956504166126251, -0.09590502083301544, 0.05464036762714386, 0.017066653817892075, 0.10792574286460876, -0.11462359130382538, -0.029905548319220543, 0.05472815781831741, -0.05508354306221008, 0.0010342509485781193, 0.15259572863578796, 0.12715071439743042, 0.26007020473480225, -0.21000142395496368, 0.05990330129861832, 0.16358548402786255, 0.03439804166555405, -0.04532141983509064, -0.005684457719326019, 0.07583026587963104, -0.06936591863632202, 0.08298549801111221, -0.03926558047533035, -0.0010717185214161873, 0.023656025528907776, -0.06792452186346054, -0.08503824472427368, -0.058434177190065384, -0.009122617542743683, 0.0008359909988939762, -0.041569724678993225, 0.04141209274530411, -0.029711758717894554, -0.005991614423692226, 0.023943467065691948, -0.0266086608171463, -0.20604301989078522, -0.1503935009241104, -0.061937667429447174, -0.0634641945362091, 0.09265246987342834, -0.026079734787344933, 0.01949063129723072, 0.04675407335162163, 0.0109175406396389, 0.07380733639001846, 0.13972768187522888, 0.08208715915679932, -0.016895566135644913, 0.2628716826438904, -0.020892534404993057, 0.054118938744068146, 0.22275769710540771, 0.05101992189884186, 0.06533236801624298, -0.010175841860473156, 0.1049925684928894, -0.14678992331027985, 0.06531703472137451, 0.10356826335191727, -0.08919064700603485, 1.0617026773060499e-32, 0.03873319923877716, 0.04179723560810089, -0.09126131981611252, 0.09836947172880173, 0.01229008287191391, -0.07916271686553955, -0.03227948397397995, 0.07314355671405792, -0.1618855893611908, -0.09709788858890533, -0.14682118594646454, -0.005989145487546921, 0.0160059817135334, 0.13063448667526245, -0.11951781809329987, -0.0799340009689331, 0.09271174669265747, 0.15468937158584595, 0.029346277937293053, -0.02457289583981037, 0.050740547478199005, -0.06659653782844543, -0.041101887822151184, 0.015312627889215946, 0.0028492510318756104, 0.09132292121648788, -0.0656125545501709, 0.12671640515327454, 0.05760879069566727, 0.06034843996167183, -0.06049113720655441, -0.006939985789358616, 0.04543094336986542, -0.12482577562332153, -0.12627877295017242, -0.11696136742830276, -0.0832921713590622, -0.10528977960348129, 0.03695128858089447, 0.038515325635671616, 0.06546445190906525, 0.10515753924846649, -0.1713811457157135, 0.004727653693407774, 0.0675974041223526, -0.11191289871931076, -0.08705315738916397, -0.05576840043067932, -0.08298251032829285, -0.06605853885412216, 0.030952777713537216, 0.014094377867877483, -0.001762455329298973, -0.17299038171768188, -0.057714931666851044, 0.05310777574777603, -0.03032935969531536, -0.09370961785316467, 0.06327623128890991, 0.10748213529586792, 0.09158451110124588, 0.12482713162899017, 0.0012027006596326828, 0.0789385735988617, 0.02657330594956875, -0.05028388649225235, 0.015068833716213703, -0.08789119124412537, -0.110817089676857, 0.025894539430737495, -0.08574027568101883, -0.06268005818128586, 0.1103094220161438, 0.038672514259815216, 0.14483299851417542, -0.14269764721393585, 0.14220690727233887, 0.0982271283864975, 0.009592648595571518, -0.0013765748590230942, -0.15293793380260468, 0.030765004456043243, -0.06364275515079498, 0.07859643548727036, 0.0571010485291481, -0.08132635802030563, -0.02543497085571289, 0.021657031029462814, -0.19823795557022095, -0.09855777025222778, 0.02559136040508747, -0.028575291857123375, -0.0921691507101059, 0.13280658423900604, 0.21724466979503632, -1.2017229358669944e-32, -0.10558018088340759, 0.07462386786937714, -0.026776619255542755, -0.15226653218269348, -0.04062753543257713, 0.05963493883609772, -0.004319641273468733, -0.17045196890830994, 0.25119900703430176, -0.09197359532117844, 0.09378597140312195, 0.022036239504814148, -0.0764622688293457, -0.07645291090011597, -0.10800851881504059, 0.030149180442094803, -0.07217472791671753, -0.07771622389554977, -0.11182749271392822, -0.0016255304217338562, 0.20429860055446625, 0.185679093003273, -0.1272621601819992, 0.08593282103538513, 0.04524607956409454, 0.0012392194475978613, 0.13300468027591705, 0.11434075981378555, 0.10543198138475418, -0.13396403193473816, 0.04311681166291237, -0.0015235841274261475, -0.23831361532211304, -0.02099514938890934, -0.0007252991199493408, 0.05064622685313225, 0.1261684149503708, -0.2596624195575714, -0.16575422883033752, -0.06694169342517853, 0.06974144279956818, 0.04758521914482117, -0.047887180000543594, 0.0933845192193985, -0.005874417722225189, -0.03180067986249924, 0.1117301732301712, -0.05412963032722473, 0.10446950793266296, -0.02282680757343769, 0.03710270673036575, -0.020200517028570175, 0.05144679546356201, 0.1715293824672699, -0.022287020459771156, -0.09116421639919281, 0.12882553040981293, -0.05168020725250244, -0.15189753472805023, 0.03332643583416939, 0.055155061185359955, 0.09274192154407501, -0.03564333915710449, -0.026414573192596436, 0.0552164651453495, 0.05977557599544525, 0.05236625671386719, -0.07874719053506851, 0.09757094085216522, -0.08533162623643875, -0.03616003319621086, -0.09888313710689545, -0.07795137166976929, -0.020966537296772003, -0.13578858971595764, 0.04555639997124672, 0.06665533781051636, -0.11210884153842926, -0.03326733037829399, -0.17875485122203827, -0.10871025174856186, -0.07409097254276276, -0.03569784760475159, 0.1340704709291458, 0.1520109325647354, 0.00858180969953537, -0.01492143515497446, 0.07428493350744247, 0.061037447303533554, 0.06691588461399078, -0.043667614459991455, -0.08686526864767075, -0.15186981856822968, 0.045237861573696136, -0.02172289974987507, -1.013955710504888e-07, 0.12739168107509613, -0.013526237569749355, -0.11520357429981232, 0.024990422651171684, -0.02434428036212921, 0.0026167824398726225, -0.16729004681110382, 0.04599274694919586, -0.0783284455537796, 0.13762357831001282, -0.08714283257722855, 0.19906997680664062, -0.09569095820188522, -0.07451950013637543, 0.03719308227300644, -0.001690918579697609, 0.09864713996648788, 0.08049573749303818, -0.0828193724155426, 0.01436914037913084, -0.06609538942575455, -0.06659050285816193, -0.03282657265663147, -0.1065821498632431, 0.02065221406519413, -0.23141837120056152, 0.15192672610282898, 0.0791570171713829, 0.07093890011310577, -0.06380832940340042, -0.005639662966132164, 0.03290002793073654, 0.08235781639814377, 0.07144497334957123, 0.07362771034240723, -0.07579012215137482, 0.06658998131752014, 0.18486946821212769, 0.05534163862466812, 0.13676846027374268, 0.08547413349151611, -0.03022148832678795, -0.03818044811487198, 0.02846347540616989, -0.06184530630707741, -0.10288242250680923, -0.07735110819339752, -0.04762545973062515, 0.11299244314432144, -0.03418237343430519, 0.024342939257621765, -0.021918904036283493, 0.0662500262260437, -0.062462396919727325, -0.1038668155670166, 0.22399872541427612, -0.044471628963947296, -0.12846869230270386, 0.040227413177490234, -0.009646005928516388, 0.17124637961387634, -0.056008003652095795, 0.08629964292049408, -0.026098094880580902], "changes": {"1wk": 13.45549551568365}}, {"text": "PREMIUM Denali Gets FDA Breakthrough Therapy Designation for Hunter Syndrome Treatment MT Newswires Wed, Jan 8, 2025, 6:51 PM 1 min read In This Article: DNLI -6.27% Denali Therapeutics (DNLI) said Wednesday the US Food and Drug Administration has given breakthrough PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DNLI", "date": "2025-01-08T18:51:44", "sentiment": {"score": 0.06692099012434483, "confidence": 0.07822555303573608, "probabilities": {"positive": 0.07822555303573608, "negative": 0.011304562911391258, "neutral": 0.9104698896408081}}, "embedding": [-0.18848274648189545, -0.18421174585819244, 0.024581940844655037, 0.0662139430642128, -0.05594528466463089, -0.14151184260845184, -0.06390182673931122, 0.236586332321167, -0.08990815281867981, 0.014296432957053185, 0.009229355491697788, 0.1480114758014679, -0.1553405523300171, 0.12524987757205963, 0.11042303591966629, 0.00898400042206049, 0.14396536350250244, 0.04212165251374245, 0.029782909899950027, -0.05637963488698006, -0.13242103159427643, 0.1526932716369629, -0.05424487590789795, 0.06035858765244484, 0.04089764505624771, -0.011858643963932991, -0.16283179819583893, -0.039311483502388, 0.09527257829904556, -0.015722176060080528, -0.09443272650241852, -0.020926401019096375, 0.07293173670768738, -0.20508329570293427, 0.06291903555393219, -0.029620204120874405, -0.1334632784128189, 0.03228688985109329, -0.052517298609018326, -0.025800619274377823, 0.1702062040567398, -0.048940259963274, -0.0791102796792984, 0.12264934182167053, 0.0010029322002083063, -0.25232192873954773, -0.31758004426956177, 0.2097286880016327, 0.07950272411108017, 0.04640369489789009, -0.04640790447592735, -0.29109424352645874, 0.15370850265026093, -0.044801775366067886, 0.015613856725394726, -0.13258621096611023, -0.08200671523809433, -0.03835875540971756, -0.024577897042036057, -0.09562526643276215, 0.06232752278447151, -0.06876233965158463, -0.10850537568330765, 0.051438115537166595, 0.11795329302549362, 0.11511441320180893, 0.09464874118566513, 0.021761275827884674, 0.12025197595357895, -0.12888377904891968, -0.004976592492312193, -0.09804166108369827, 0.15191909670829773, -0.009935032576322556, 0.045170288532972336, -0.03811323642730713, 0.09187262505292892, -0.018231326714158058, 0.2624771296977997, -0.12460856139659882, 0.24232333898544312, 0.017938027158379555, 0.09589957445859909, 0.0069913617335259914, 0.04927746579051018, 0.05282601714134216, -0.12927360832691193, -0.11557330936193466, -0.0940430536866188, -0.18254800140857697, 0.0063270749524235725, -0.11839015036821365, -0.1946716457605362, -0.08620313555002213, -0.20784097909927368, 0.011283054947853088, -0.252195805311203, 0.015660924836993217, -0.16015322506427765, 0.052166011184453964, -0.02458365261554718, -0.00806355755776167, -0.25109460949897766, -0.12844866514205933, -0.08322861045598984, -0.13977812230587006, 0.1419379860162735, 0.1483566164970398, 0.0886138305068016, 0.23638096451759338, -0.021055106073617935, 0.1848859339952469, 0.13021303713321686, 0.05323350429534912, -0.04145050793886185, 0.27946561574935913, -0.013144220225512981, -0.04942729324102402, 0.23457367718219757, -0.15073618292808533, 0.0917586162686348, 0.04154655709862709, -0.0011402078671380877, -0.13143685460090637, 0.06610247492790222, 0.052216820418834686, 0.0038545234128832817, 9.31917521526112e-33, 0.07608464360237122, 0.14712606370449066, -0.034427717328071594, 0.08946561068296432, 0.07684903591871262, -0.08218705654144287, -0.05434541404247284, -0.08167912065982819, -0.1731477528810501, -0.15973244607448578, -0.24808360636234283, 0.06549907475709915, 0.00594900781288743, 0.22207799553871155, -0.18007606267929077, -0.1126934066414833, 0.0964834988117218, 0.1505288928747177, 0.14937415719032288, 0.011309182271361351, 0.10270196199417114, -0.0062792194075882435, -0.04498860612511635, 0.039455167949199677, -0.017850510776042938, 0.13176292181015015, -0.0033336984924972057, 0.19607816636562347, 0.10611961036920547, 0.036143481731414795, -0.1929340660572052, 0.053503114730119705, 0.04149366170167923, -0.018101342022418976, 0.046921372413635254, -0.019770076498389244, -0.0692211240530014, -0.05867929011583328, -0.002426119986921549, -0.024994859471917152, 0.08152630180120468, 0.11944428086280823, -0.26961496472358704, -0.006539204157888889, -0.009435942396521568, 0.02143867313861847, -0.15212707221508026, -0.06099622696638107, -0.045276984572410583, -0.15954026579856873, 0.0023382501676678658, 0.19156765937805176, -0.1943686306476593, -0.13302160799503326, -0.00983345415443182, -0.035854194313287735, 0.05398564040660858, -0.09789181500673294, 0.16670499742031097, 0.044908568263053894, 0.16941501200199127, 0.03929200395941734, 0.10506284236907959, -0.020501406863331795, 0.031226791441440582, 0.00814967043697834, -0.06554850935935974, -0.09948751330375671, -0.051233623176813126, 0.05241771787405014, 0.014704451896250248, -0.004221779294312, -0.05515876039862633, 0.042891427874565125, -0.07394877076148987, -0.0640912875533104, 0.12310828268527985, 0.15213151276111603, 0.1323975771665573, 0.09364623576402664, -0.008727514185011387, -0.05298374965786934, 0.05964024364948273, 0.13293957710266113, 0.0568927638232708, 0.0036552497185766697, -0.06834676861763, 0.09663111716508865, -0.004055427387356758, -0.10770702362060547, -0.05549385026097298, -0.03508187085390091, 0.02350928820669651, 0.03628304973244667, 0.08865295350551605, -1.2672362482425945e-32, -0.19978852570056915, 0.06240589916706085, -0.04622984677553177, -0.14494600892066956, -0.1435636281967163, -0.042330916970968246, -0.2471522092819214, 0.05395464971661568, 0.4042474329471588, 0.07427267730236053, 0.170950248837471, 0.07593454420566559, -0.11848140507936478, 0.02325107343494892, -0.007244230248034, 0.10904581099748611, -0.10429377853870392, -0.07120302319526672, -0.17897406220436096, -0.10866282880306244, 0.24107563495635986, 0.14719264209270477, -0.21271571516990662, 0.1770203411579132, 0.16614511609077454, -0.033449672162532806, 0.11202935129404068, 0.33131852746009827, -0.013057833537459373, -0.21774452924728394, 0.0053538912907242775, -0.05617864429950714, -0.22116011381149292, -0.015289696864783764, -0.07366408407688141, 0.07307031005620956, 0.15023452043533325, -0.105303093791008, -0.17526760697364807, -0.09322535991668701, 0.06071494519710541, -0.10200423747301102, -0.09734538942575455, 0.22560785710811615, 0.1089741438627243, -0.028770651668310165, 0.0311716441065073, -0.12924663722515106, 0.03556709736585617, 0.07625874876976013, 0.08177195489406586, -0.10171233117580414, 0.1464949995279312, 0.09483601897954941, -0.15673823654651642, -0.0040849051438272, 0.07092136889696121, 0.035346463322639465, 0.02397838607430458, 0.021853405982255936, 0.11446723341941833, 0.11900463700294495, -0.2717660963535309, -0.10589469969272614, 0.04864206537604332, 0.04259278252720833, 0.11139998584985733, -0.1286902129650116, 0.06056775525212288, -0.06985335052013397, 0.01610708236694336, -0.01645880937576294, -0.1725321263074875, -0.04231039434671402, -0.19161099195480347, 0.00970395840704441, 0.007131583988666534, -0.028797952458262444, 0.022380517795681953, -0.08157359808683395, -0.12417174130678177, -0.1413319706916809, -0.07192996144294739, 0.20997029542922974, 0.14402493834495544, 0.01757848635315895, 0.052774958312511444, -0.04859358072280884, -0.1395832896232605, 0.09611722826957703, -0.1294867843389511, -0.14546887576580048, -0.2678060829639435, 0.05876684933900833, 0.0053895218297839165, -1.0048523790828767e-07, 0.2993009388446808, -0.08517281711101532, -0.2246074229478836, 0.09225796908140182, 0.046186190098524094, -0.0037936153821647167, -0.24961355328559875, -0.02123584784567356, -0.019651008769869804, 0.14609535038471222, -0.13566692173480988, 0.20597487688064575, 0.0452101044356823, -0.1143655851483345, 0.013281811028718948, -0.026463162153959274, 0.11245143413543701, 0.18248683214187622, -0.12060441821813583, -0.07987779378890991, 0.08499155938625336, 0.0463482029736042, 0.08462317287921906, -0.16410000622272491, 0.015993965789675713, -0.18696583807468414, 0.17188872396945953, 0.1251324713230133, 0.13455943763256073, -0.10419405996799469, -0.03643462434411049, 0.085651695728302, -0.006182736251503229, 0.0963893011212349, 0.06245454400777817, -0.009502810426056385, 0.1285393238067627, 0.09754081070423126, 0.02905283309519291, 0.0005549844354391098, 0.04795658215880394, -0.1109931617975235, 0.003583687823265791, 0.1241200715303421, -0.21643881499767303, -0.0946914479136467, -0.09037856012582779, -0.04694044589996338, 0.24824728071689606, 0.007613568566739559, 0.05563506484031677, -0.04391976073384285, 0.1968676894903183, -0.10125745832920074, -0.18877531588077545, 0.12922319769859314, 0.004694708622992039, -0.137908473610878, -0.01480481680482626, 0.07707994431257248, 0.18654243648052216, -0.26428747177124023, 0.08475837856531143, 0.06012360751628876], "changes": {"1wk": 1.1764705882352942}}, {"text": "Denali's ALS Study Fails to Meet Primary and Secondary Endpoints Zacks Equity Research Tue, Jan 7, 2025, 10:14 PM 4 min read In This Article: DNLI -6.27% SNY -1.82% Denali Therapeutics Inc . DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform trial is evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS). DNL343 is a novel small molecule ALS therapeutic candidate that targets eIF2B, a central regulator of the integrated stress response. Shares of DNLI have lost 6.5% in the past six months compared with the industry\u2019s 6.4% decline. Zacks Investment Research Image Source: Zacks Investment Research DNLI\u2019s ALS Study Fails A total of 186 participants who were randomized to receive DNL343 treatment were compared to 139 participants randomized to receive placebo in this regimen (n=63) or shared from a concurrently enrolling regimen (n=76). ALS causes the progressive degeneration of motor neurons, resulting in muscle weakness and atrophy. The most prevalent adult-onset progressive motor neuron disease, ALS affects approximately 30,000 people in the United States and an estimated 500,000 people worldwide. Results showed that the study did not meet the primary endpoint of efficacy in slowing disease progression as compared with placebo. The primary endpoint was evaluated as a change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) and survival through week 24. Key secondary endpoints, measuring muscle strength and respiratory function, were also not statistically different between the active and placebo groups at week 24. DNL343 was found to be well tolerated. Denali will report additional data later in 2025, including neurofilament light (NfL) and other fluid biomarkers, data from pre-specified subgroups, and extended findings from the active treatment extension period. Denali will evaluate the data before determining the next steps. DNLI\u2019s Other Pipeline Updates Denali and partner Sanofi SNY were co-developing SAR443820/DNL788. However, Sanofi informed Denali that the K2 phase II study evaluating the safety and efficacy of oditrasertib (SAR443820/DNL788) on serum neurofilament light chain levels in participants with multiple sclerosis was discontinued. The decision was taken after the study did not meet the primary and key secondary endpoints. We remind investors that Sanofi had earlier discontinued the development of SAR443820/DNL788 for the treatment of ALS, based on the results of the phase II HIMALAYA study, which did not meet the primary endpoint. Meanwhile, Denali and partner Sanofi are also developing SAR443122/DNL758 (eclitasertib), a peripheralRIPK1 inhibitor, for the treatment of ulcerative colitis. Sanofi is currently conducting a phase II study on this candidate. Story Continues Denali\u2019s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome). Denali recently initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor, is being evaluated in participants with LRRK2-associated Parkinson\u2019s disease (LRRK2-PD). The phase IIa study will evaluate safety and biomarkers associated with oral daily dosing of BIIB122 in approximately 50 participants with Parkinson\u2019s disease and LRRK2 pathogenic mutations confirmed by genetic testing. BIIB122 is also being evaluated in the ongoing global phase IIb LUMA study in participants with early-stage Parkinson\u2019s disease with or without an LRRK2 mutation in collaboration with Biogen BIIB. The LUMA study is being conducted by Biogen. This study is expected to enroll approximately 640 participants with early-stage Parkinson\u2019s disease, including eligible participants with LRRK2 mutations. Denali also has multiple early-stage clinical and preclinical programs in its pipeline. DNLI's Zacks Rank and Stock to Consider Denali currently carries a Zacks Rank #4 (Sell). A better-ranked stock in the biotech sector is Immunocore Holdings plc IMCR, which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 60 days, estimates for Immunocore\u2019s 2024 loss per share have narrowed from $1.18 to 94 cents. Loss per share estimates for 2025 have narrowed from $1.70 to $1.57 during the same time frame. IMCR\u2019s earnings beat estimates in two of the trailing four quarters and missed the same on the remaining two occasions, the average surprise being 25.57%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DNLI", "date": "2025-01-07T22:14:00", "sentiment": {"score": -0.8585410565137863, "confidence": 0.9001877903938293, "probabilities": {"positive": 0.04164673388004303, "negative": 0.9001877903938293, "neutral": 0.05816545709967613}}, "embedding": [-0.05981270223855972, -0.191507026553154, 0.013840081170201302, -0.05237215757369995, -0.04286681115627289, -0.048294536769390106, -0.1317618191242218, 0.14677545428276062, 0.05967864766716957, 0.04267077147960663, -0.13100257515907288, 0.06935269385576248, -0.054211996495723724, -0.051950108259916306, -0.039112355560064316, 0.015848547220230103, -0.02657521516084671, 0.03960736095905304, -0.1500791758298874, 0.02951912209391594, 0.06223239377140999, 0.08094309270381927, -0.05217229947447777, 0.044881388545036316, -0.04825222119688988, 0.09538877010345459, -0.13672029972076416, -0.01342681609094143, -0.10164312273263931, -0.020741190761327744, 0.14962735772132874, 0.02888336218893528, -0.008720864541828632, -0.031987451016902924, -0.015028582885861397, 0.01395646296441555, -0.16518019139766693, 0.07114876806735992, -0.14315403997898102, -0.11862929165363312, -0.045811526477336884, 0.0008127228356897831, 0.04595283046364784, -0.05535265430808067, 0.06778768450021744, -0.1737976223230362, -0.1545647382736206, -0.0009208004921674728, -0.020901614800095558, 0.05819540098309517, -0.023212596774101257, -0.14596468210220337, 0.20794495940208435, 0.09218283742666245, 0.029704123735427856, 0.06996224820613861, -0.058402419090270996, 0.05792895704507828, -0.10043627768754959, 0.11485865712165833, 0.030979687348008156, -0.03802211210131645, 0.03462476655840874, -0.07525715976953506, 0.0491795614361763, 0.10675592720508575, -0.0037546800449490547, -0.1333072930574417, -0.05744228512048721, -0.061057668179273605, -0.005498952232301235, -0.07173046469688416, -0.0059845224022865295, 0.05380423367023468, 0.03613301366567612, -0.029513675719499588, 0.11734277009963989, 0.033871546387672424, 0.19925019145011902, -0.12799891829490662, 0.14445748925209045, 0.1640123426914215, 0.0920557901263237, 0.04547302424907684, 0.08199381828308105, 0.056391309946775436, 0.00046306289732456207, 0.12338587641716003, -0.046140581369400024, 0.07064712047576904, 0.04493733495473862, -0.09658047556877136, -0.0785524770617485, 0.014858853071928024, 0.044852785766124725, -0.03774794563651085, -0.10968570411205292, 0.08876310288906097, 0.020447038114070892, -0.010418863967061043, 0.02252236008644104, 0.0813213586807251, 0.030605481937527657, -0.19993212819099426, -0.06848565489053726, -0.018759382888674736, 0.12503288686275482, -0.0896802619099617, 0.0027667321264743805, 0.14819234609603882, 0.032483525574207306, -0.00538908876478672, -0.07561472058296204, 0.04923669621348381, 0.04673222452402115, 0.13902628421783447, -0.03373100608587265, 0.07016340643167496, 0.11256324499845505, -0.06016480177640915, 0.09575879573822021, 0.027812926098704338, 0.08478744328022003, -0.15639129281044006, 0.022990746423602104, 0.09591014683246613, -0.15978063642978668, 1.1690267809040633e-32, 0.028913982212543488, -0.10565868020057678, -0.0431734099984169, 0.037849582731723785, -0.013850627467036247, -0.1493193656206131, -0.019691407680511475, 0.11572130024433136, 2.4376437067985535e-05, -0.12306028604507446, -0.10123591125011444, -0.019845860078930855, 0.014536209404468536, 0.06539992243051529, -0.03159209340810776, -0.04265005886554718, 0.0034004193730652332, 0.037388965487480164, -0.03830583766102791, -0.07630941271781921, 0.08251270651817322, -0.02482457458972931, -0.056872837245464325, -0.0015615345910191536, 0.041384775191545486, -0.12030304968357086, -0.01792163774371147, 0.13273751735687256, 0.09886682778596878, 0.007453500758856535, -0.11578534543514252, -0.15051612257957458, 0.03326820582151413, -0.1297438144683838, 0.04354800656437874, -0.024445440620183945, -0.018627982586622238, 0.055888112634420395, 0.03417787328362465, 0.1308313012123108, 0.08420867472887039, 0.09769947826862335, -0.14974936842918396, -0.07343728840351105, 0.07740109413862228, -0.1071556955575943, 0.008112271316349506, -0.03361125290393829, 0.007230412680655718, -0.0037001892924308777, 0.001610366627573967, -0.025152312591671944, 0.053711626678705215, -0.07375003397464752, -0.0354217030107975, 0.03748023509979248, -0.06136586517095566, -0.060224760323762894, 0.1471012830734253, 0.06975218653678894, -0.04095843434333801, 0.05064065009355545, 0.013136222027242184, -0.030251698568463326, 0.016531290486454964, 0.05704816058278084, 0.040582817047834396, -0.0046176305040717125, -0.19449009001255035, -0.04457922652363777, 0.06063247472047806, -0.1461101770401001, 0.10887661576271057, 0.05106133595108986, 0.04476046562194824, -0.06872134655714035, 0.037735164165496826, 0.13251493871212006, 0.03894880786538124, -0.007160947658121586, -0.03831366449594498, 0.02919045090675354, -0.17723815143108368, 0.15265658497810364, 0.06177401542663574, -0.04602392017841339, -0.029527923092246056, -0.060807935893535614, -0.10364507883787155, -0.0925719141960144, 0.03334663063287735, -0.026983395218849182, -0.04076032340526581, 0.04514838755130768, 0.10609802603721619, -1.4301937076659435e-32, -0.1158033013343811, 0.09860081225633621, -0.007899507880210876, -0.01298857294023037, 0.04454672336578369, 0.12217623740434647, 0.14919352531433105, -0.10248015820980072, 0.17683327198028564, -0.18965168297290802, 0.06615517288446426, 0.01025297399610281, -0.06313275545835495, -0.027290036901831627, -0.01906665414571762, 0.006236237473785877, -0.28924477100372314, 0.05361947789788246, -0.065379299223423, 0.014851757325232029, 0.24819397926330566, 0.16239528357982635, 0.01942651905119419, 0.11668239533901215, -0.03352152556180954, 0.054134801030159, 0.06473786383867264, 0.12112186849117279, 0.012634236365556717, -0.05061405897140503, 0.08163093775510788, -0.027617746964097023, -0.16961055994033813, -0.020923849195241928, -0.11727894842624664, -0.022965770214796066, -0.05515081807971001, -0.1176079511642456, -0.17016136646270752, -0.045434288680553436, 0.09650148451328278, 0.19708627462387085, 0.12300296127796173, 0.060171958059072495, 0.05157047137618065, -0.04777870327234268, 0.028026040643453598, -0.20490509271621704, 0.059875547885894775, -0.0468745157122612, -0.006361851468682289, -0.0334148183465004, -0.041469935327768326, -0.015460774302482605, 0.03816227614879608, -0.06488271802663803, 0.1129189059138298, 0.06559135764837265, -0.17761589586734772, 0.06319485604763031, -0.08782055974006653, 0.007461243774741888, 0.010165554471313953, 0.0004474800080060959, 0.112810418009758, 0.019962627440690994, 0.052542127668857574, -0.032354485243558884, 0.03897494077682495, -0.0528559610247612, -0.18569988012313843, -0.11196789145469666, 0.0011233100667595863, -0.007144580595195293, -0.07912608236074448, 0.03302401304244995, -0.14478468894958496, -0.003597852773964405, 0.027650481089949608, -0.03212857246398926, -0.08516288548707962, -0.02516338974237442, -0.0680321678519249, 0.0547185093164444, -0.016822710633277893, -0.0029022200033068657, 0.02401958964765072, -0.10018502175807953, -0.0027942024171352386, 0.0544729009270668, -0.0861186608672142, -0.01742682233452797, -0.09743022918701172, 0.08034075796604156, -0.06580302864313126, -1.0120696458670864e-07, 0.12324516475200653, 0.029477126896381378, 0.06563400477170944, -0.006022457033395767, -0.014209166169166565, -0.11192917823791504, 0.030324695631861687, 0.08794824779033661, -0.09298393875360489, 0.09387358278036118, 0.11323322355747223, 0.11294104158878326, -0.06891492754220963, -0.01920231804251671, 0.013887456618249416, -0.04253145679831505, 0.05735133960843086, 0.06790250539779663, -0.07497219741344452, -0.05754178389906883, 0.09877992421388626, -0.03221587836742401, -0.012866726145148277, -0.11251231282949448, 0.03621773421764374, -0.10852033644914627, 0.09632689505815506, 0.14300674200057983, -0.030648376792669296, -0.17690891027450562, -0.03422638401389122, 0.08577689528465271, 0.010194968432188034, 0.006597653031349182, -0.05604958534240723, -0.13159579038619995, 0.043324775993824005, 0.11060422658920288, -0.12016896903514862, 0.16928686201572418, -0.030734937638044357, 0.027529049664735794, -0.033522963523864746, 0.028883863240480423, 0.06121613085269928, -0.05183204263448715, -0.0345059372484684, 0.0698503702878952, 0.05971865355968475, -0.11216185241937637, -0.042538490146398544, 0.027517320588231087, -0.008755777031183243, 0.052688464522361755, -0.12819284200668335, 0.14702171087265015, -0.21517780423164368, 0.1277199536561966, -0.009340374730527401, -0.1067701131105423, 0.030776023864746094, -0.11068782210350037, -0.002341877669095993, 0.016578473150730133], "changes": {"1wk": -11.520304527386392}}, {"text": "Denali Therapeutics price target lowered to $32 from $35 at BTIG TipRanks Wed, Jan 8, 2025, 3:25 PM 1 min read In This Article: DNLI -6.27% https://www.tipranks.com/news/the-fly/progyny-announces-acquisition-of-benefitbump-terms-not-disclosed BTIG analyst Thomas Shrader lowered the firm\u2019s price target on Denali Therapeutics ( DNLI ) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2/3 HEALEY trial which was testing an agonist of eIF2B for amyotrophic lateral sclerosis. The DNL343 failure is sobering as the program was backed by convincing pre-clinical data showing reduced aggregation of key drivers of ALS pathology such as TDP-43, the analyst tells investors in a research note. The firm adds that it was one of the last legacy programs at Denali as management has made it clear that the pipeline will be increasingly focused on the TV side of development. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Published first on TheFly \u2013 the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders\u2019 Hot Stocks on TipRanks >> Read More on DNLI: 3 Best Stocks to Buy Now, 1/7/2025, According to Top Analysts Denali Therapeutics price target lowered to $87 from $90 at H.C. Wainwright Denali Therapeutics\u2019 ALS Drug Fails Phase 2/3 Trial Denali Therapeutics initiated with an Outperform at Baird Closing Bell Movers: Inari adds 21% after confirmed Stryker buyout View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DNLI", "date": "2025-01-08T15:25:39", "sentiment": {"score": -0.6015705391764641, "confidence": 0.679762601852417, "probabilities": {"positive": 0.07819206267595291, "negative": 0.679762601852417, "neutral": 0.24204528331756592}}, "embedding": [-0.1060420349240303, -0.22938808798789978, -0.03714185208082199, -0.03146208077669144, 0.003726803697645664, 0.012216855771839619, 0.028292564675211906, 0.22748404741287231, 0.03777968883514404, 0.09460382163524628, -0.06348235160112381, 0.12176042050123215, -0.05309276282787323, -0.0032751148100942373, -0.07589409500360489, 0.02339601144194603, 0.06178871542215347, -0.06070151552557945, -0.08758042007684708, -0.030336128547787666, -0.1037999615073204, 0.07117244601249695, -0.0215139277279377, 0.06346727907657623, 0.08701091259717941, 0.00019338182755745947, -0.09125994145870209, 0.004673514049500227, -0.0990615263581276, -0.06246684491634369, -0.05217144265770912, 0.04049132391810417, -0.027859510853886604, -0.13134628534317017, -0.012154527939856052, -0.04655955731868744, -0.15185140073299408, 0.10565446317195892, 0.009789654053747654, -0.0031132164876908064, 0.05134883150458336, -0.006030848249793053, -0.19860996305942535, -0.029558883979916573, 0.020885180681943893, -0.19013819098472595, -0.14931455254554749, 0.04934586584568024, 0.09564108401536942, 0.10110417008399963, -0.19849760830402374, -0.10025402158498764, 0.12144197523593903, 0.06588725000619888, -0.0764923244714737, 0.05619487538933754, -0.06824304163455963, 0.04198832809925079, 0.022890660911798477, 0.022037766873836517, 0.07571917772293091, -0.10855430364608765, 0.08787743747234344, -0.06680060923099518, 0.15849868953227997, 0.015357316471636295, -0.0027659821789711714, -0.05284038186073303, 0.011729108169674873, -0.028767436742782593, 0.0894666239619255, -0.06145563721656799, -0.0065177250653505325, -0.020535223186016083, -0.014189206063747406, 0.05282158404588699, 0.1407463550567627, -0.03280319646000862, 0.16124455630779266, -0.0522162951529026, 0.11339247971773148, 0.02432296983897686, 0.051562316715717316, 0.0017072969349101186, 0.08623358607292175, -0.007319081574678421, 0.08031940460205078, 0.03176170960068703, 0.07230886816978455, -0.013945912942290306, 0.10203821212053299, -0.07036534696817398, -0.15400724112987518, -0.016839200630784035, 0.04623336344957352, 0.026938583701848984, -0.18033041059970856, 0.036232128739356995, 0.04662718251347542, 0.01604308933019638, 0.07001513987779617, 0.049415308982133865, -0.05945092439651489, -0.1817626804113388, -0.04490377753973007, -0.1437257081270218, 0.192423477768898, -0.04192067310214043, 0.06153104454278946, 0.04798523336648941, -0.07431158423423767, 0.07367127388715744, -0.01677979715168476, 0.011838667094707489, -0.08152475953102112, 0.2333124876022339, -0.07091104239225388, -0.02461400255560875, 0.1963391900062561, -0.060210466384887695, 0.08433852344751358, 0.009297766722738743, 0.05830458551645279, -0.06226013973355293, 0.037803199142217636, 0.14103016257286072, -0.2704576253890991, 1.3960519150566918e-32, 0.05826343968510628, 0.02954254485666752, -0.07795518636703491, -0.07372812926769257, -0.04400312528014183, -0.10793250054121017, 0.019657349213957787, 0.07883243262767792, -0.13260973989963531, -0.0765945166349411, -0.22934290766716003, 0.025711651891469955, -0.022165345028042793, -0.011623314581811428, -0.04015883430838585, -0.14983445405960083, -0.029670652002096176, 0.08867090195417404, -0.08304884284734726, -0.0492510125041008, 0.06948266178369522, -0.0020861432421952486, -0.1277671456336975, -0.0595712773501873, 0.011164190247654915, -0.03668389096856117, -0.06797663122415543, 0.11797518283128738, 0.13228407502174377, 0.03188237547874451, -0.0868382677435875, -0.028542064130306244, 0.014591839164495468, -0.10377144813537598, 0.042835600674152374, -0.09566093236207962, -0.13307766616344452, -0.020451681688427925, 0.028169522061944008, 0.07292677462100983, 0.018649045377969742, 0.26368406414985657, -0.07109618932008743, -0.12017124891281128, 0.048047300428152084, -0.034127019345760345, -0.060647811740636826, -0.06283024698495865, -0.009177830070257187, -0.08049985766410828, -0.03893391042947769, 0.021409358829259872, 0.03715747967362404, -0.06385575234889984, -0.02528219297528267, 0.031615279614925385, -0.06735527515411377, -0.0751064345240593, 0.13023094832897186, 0.11858922988176346, -0.0011575540993362665, 0.08663196861743927, 0.04156515374779701, -0.0948094055056572, -0.06807468086481094, 0.09730200469493866, 0.035530392080545425, 0.04437127709388733, -0.14225269854068756, -0.00919322855770588, 0.045283686369657516, 0.01584068313241005, 0.13500894606113434, -0.009715858846902847, 0.07059933245182037, -0.08307576924562454, 0.044416557997465134, 0.07300219684839249, 0.1017962098121643, -0.11944444477558136, 0.08652114123106003, -0.0025759502314031124, -0.052945565432310104, 0.11383035033941269, 0.08599482476711273, -0.070309117436409, -0.07929456979036331, -0.05702449753880501, -0.15356823801994324, -0.07855711132287979, 0.008172819390892982, 0.06199323385953903, -0.11260060220956802, 0.056769244372844696, 0.013975352048873901, -1.2718665204904835e-32, -0.13597308099269867, 0.09423579275608063, -0.010611479170620441, 0.005894736852496862, -0.024044951424002647, 0.06607569009065628, 0.05768750235438347, -0.07615215331315994, 0.20588549971580505, 0.011674650944769382, 0.07290925085544586, 0.08197576552629471, -0.10234459489583969, 0.026075664907693863, -0.07304231077432632, 0.019800130277872086, -0.16154316067695618, -0.04516122490167618, -0.017920948565006256, -0.11594712734222412, 0.16728538274765015, 0.19596903026103973, -0.06990627944469452, 0.17450721561908722, -0.02615591324865818, 0.14050543308258057, 0.12135821580886841, 0.15890580415725708, -0.026610542088747025, -0.012678517960011959, -0.06904541701078415, 0.010856332257390022, -0.16465319693088531, 0.055017851293087006, -0.09527608007192612, 0.10348053276538849, 0.018667807802557945, -0.15353773534297943, -0.08732547610998154, 0.004107980988919735, 0.09286393225193024, 0.10378623753786087, 0.12731526792049408, -0.04452643543481827, 0.09508925676345825, -0.05069487541913986, 0.08712742477655411, -0.061377301812171936, 0.10030479729175568, 0.06513730436563492, -0.018784916028380394, -0.02377364970743656, 0.04326428100466728, 0.10500728338956833, -0.10975630581378937, -0.034124668687582016, 0.06028088927268982, 0.04277739301323891, -0.17089655995368958, 0.034848615527153015, 0.02038840763270855, 0.1448090672492981, -0.027302639558911324, 0.001805478590540588, 0.023988895118236542, 0.0726502537727356, 0.03283020481467247, -0.018485108390450478, 0.02996685355901718, -0.12548108398914337, -0.0753600001335144, -0.11270969361066818, 0.08369401097297668, -0.08501271158456802, -0.0665988177061081, 0.10351790487766266, -0.06645078957080841, -0.059039950370788574, -0.008858324959874153, -0.02329001948237419, -0.004773338325321674, -0.02358449064195156, -0.004044201225042343, 0.048191189765930176, 0.009670520201325417, 0.08830168098211288, -0.014657765626907349, -0.029276840388774872, -0.09965009242296219, 0.04319724068045616, -0.0904792845249176, -0.1852983832359314, -0.02465098723769188, 0.0970778837800026, -0.01985587365925312, -1.0035263642294012e-07, 0.10982218384742737, 0.04430141672492027, 0.015169002115726471, 0.03737572580575943, 0.04770265892148018, -0.15180519223213196, 0.0033658223692327738, 0.09632657468318939, 0.0009698803769424558, 0.13948461413383484, 0.016114596277475357, 0.10999049246311188, -0.15823067724704742, -0.07128996402025223, -0.0015873119700700045, -0.059842947870492935, -0.022955480962991714, 0.07581871002912521, -0.09550340473651886, -0.09766141325235367, 0.11428303271532059, 0.04252542927861214, 0.056709371507167816, -0.0030012724455446005, 0.03561372682452202, -0.036138277500867844, 0.04227650910615921, 0.06892966479063034, 0.05406251549720764, -0.052612777799367905, -0.023479629307985306, 0.08133407682180405, 0.11394469439983368, 0.02979743853211403, 0.05569867417216301, -0.048656903207302094, -0.001594926929101348, 0.1635049283504486, -0.06493895500898361, 0.15644873678684235, -0.04861803352832794, -0.08769350498914719, -0.0613233782351017, -0.025404542684555054, 0.014506978914141655, -0.038228362798690796, -0.12963153421878815, 0.029615109786391258, 0.1324329376220703, -0.10186456888914108, 0.08979365974664688, -0.03415802866220474, -0.0031470677349716425, 0.05194205790758133, -0.039691176265478134, 0.09904763847589493, -0.15634971857070923, 0.09340997040271759, -0.15152466297149658, -0.005081454757601023, 0.02381681650876999, -0.18967631459236145, 0.0030904037412256002, 0.12379331141710281], "changes": {"1wk": -11.811765782973344}}, {"text": "Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) Denali Therapeutics Inc. Wed, Jan 8, 2025, 4:00 PM 6 min read In This Article: DNLI -6.27% Denali Therapeutics Inc. Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment of individuals with Hunter syndrome (MPS II). This designation is in addition to Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation, all previously granted by the FDA for tividenofusp alfa in Hunter syndrome. Denali expects to submit a Biologics License Application (BLA) for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway. \u201cFDA Breakthrough Therapy Designation is another significant achievement in the development of tividenofusp alfa, our first Enzyme TransportVehicle\u2122 program, uniquely designed to optimize enzyme delivery to both brain and body, addressing the full spectrum of Hunter syndrome, a progressive and devastating disease,\u201d said Carole Ho, M.D., Chief Medical Officer of Denali Therapeutics. \u201cData from the open-label Phase 1/2 study have shown promising results, with positive effects on evidence-based surrogate endpoints and early signs of improved clinical outcomes in participants with Hunter syndrome. We are grateful to the FDA for recognizing the potential of tividenofusp alfa as a meaningful treatment option for individuals with Hunter syndrome. We look forward to continued collaboration with the FDA to bring an effective therapy to the Hunter syndrome community as soon as possible.\u201d Breakthrough Therapy Designation is intended to expedite the development and review of therapeutic candidates that are under investigation for the treatment of serious or life-threatening conditions. Breakthrough Therapy Designation requires preliminary clinical evidence suggesting a candidate may provide substantial improvement over available therapy on at least one clinically significant endpoint. This designation provides Denali with more intensive FDA guidance, including involvement of senior reviewers, and eligibility for rolling review and priority review of the marketing application. About Hunter Syndrome (MPS II) Hunter syndrome (MPS II) is a rare genetic disease that affects over 2,000 individuals in commercially accessible geographies, primarily males, and leads to physical, cognitive, and behavioral symptoms. Hunter syndrome is caused by mutations in the iduronate-2-sulfatase (IDS) gene, which leads to a deficiency of the IDS enzyme. Symptoms often begin emerging around age two and include physical complications, including organ dysfunction, joint stiffness, hearing loss and impaired growth, and neurocognitive symptoms with impaired development. The disease is characterized by a buildup of glycosaminoglycans (GAGs) in lysosomes \u2014 the part of the cell that breaks down materials including GAGs. The current standard of care, enzyme replacement therapy, partially treats physical symptoms but does not cross the blood-brain barrier, and as a result, cognitive and behavioral symptoms experienced by the majority of individuals with Hunter syndrome are not addressed. Therapies that address the range of behavioral, cognitive, and physical manifestations of the disease are recognized as an unmet need for the Hunter syndrome community. 1 Story Continues About Tividenofusp Alfa Tividenofusp alfa (or DNL310) is composed of iduronate 2-sulfatase (IDS) fused to Denali\u2019s proprietary Enzyme TransportVehicle\u2122 (ETV), which is engineered for active transport into the brain and broad delivery throughout the body with the goal of addressing behavioral, cognitive, and physical symptoms of Hunter syndrome (MPS II). In 2021, the U.S. Food and Drug Administration granted Fast Track designation to tividenofusp alfa for the treatment of patients with Hunter syndrome (MPS II). In 2022, the European Medicines Agency granted tividenofusp alfa Priority Medicines designation. Denali has announced the outcome of a meeting with the FDA providing a path to filing a biologics license application (BLA) for accelerated approval and subsequent conversion to full approval for the treatment of Hunter syndrome (MPS II). Tividenofusp alfa is an investigational drug and its safety and efficacy profile has not yet been established. Tividenofusp alfa has not been approved by any Health Authority for any use. About Denali Therapeutics Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's plans, timelines, and expectations related to tividenofusp alfa (DNL310), including interactions with the FDA, the timing of planned regulatory filings, and the timing, pathway, and likelihood of regulatory approval; Denali\u2019s overall development plans; and statements made by Denali\u2019s Chief Medical Officer. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: Denali\u2019s dependence on successful development of its BBB platform technology and TV-enabled product candidates; Denali\u2019s ability to initiate and enroll patients in its current and future clinical trials; Denali\u2019s ability to conduct or complete clinical trials on expected timelines; Denali\u2019s reliance on third parties for the manufacture and supply of its product candidates for clinical trials; the potential for clinical trial results to differ from preclinical, early clinical, preliminary or expected results; the risk of significant adverse events, toxicities, or other undesirable side effects; the risk that results from early clinical biomarker studies will not translate to clinical benefit in late clinical studies; the risk that product candidates may not receive regulatory approval necessary to be commercialized; developments relating to Denali\u2019s competitors and its industry, including competing product candidates and therapies; Denali\u2019s ability to obtain, maintain, or protect intellectual property rights; and other risks and uncertainties. In light of these risks, uncertainties, and assumptions, the forward-looking statements in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Information regarding additional risks and uncertainties may be found in Denali\u2019s Annual and Quarterly Reports filed on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 28, 2024, and November 6, 2024, respectively, and Denali\u2019s future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali\u2019s expectations, except as required by law. References Muenzer, J., et al. Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses. Mol Genet Metab . 2024 Aug;142(4):108535 Investor Contact Laura Hansen, Ph.D. Vice President, Investor Relations (650) 452-2747 hansen@dnli.com Media Contact Rich Allan FGS Global (503) 851-0807 rich.allan@fgsglobal.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DNLI", "date": "2025-01-08T16:00:00", "sentiment": {"score": 0.7639622474089265, "confidence": 0.7727819085121155, "probabilities": {"positive": 0.7727819085121155, "negative": 0.008819661103188992, "neutral": 0.21839845180511475}}, "embedding": [-0.11286880075931549, -0.20950660109519958, 0.0067696403712034225, -0.0461091473698616, -0.11066380143165588, -0.0705094039440155, -0.10341157019138336, 0.22748911380767822, -0.02909288927912712, 0.04954821243882179, -0.0694313570857048, 0.08756624162197113, -0.10535798966884613, 0.21864989399909973, -0.02019846811890602, 0.08978527784347534, 0.07441960275173187, 0.04042881354689598, -0.004254680126905441, -0.041980430483818054, -0.05047629028558731, 0.057497039437294006, -0.05430842563509941, 0.04479218274354935, 0.015036877244710922, -0.01492032315582037, -0.1231185719370842, -0.03900455683469772, -0.08689425885677338, -0.004051417112350464, -0.04208642244338989, 0.08678758144378662, -0.02175598032772541, -0.09818105399608612, -0.0016667963936924934, 0.034494757652282715, -0.08190619200468063, -0.002642940729856491, -0.1287579983472824, -0.07075446099042892, 0.05852551758289337, -0.004001002758741379, -0.10885201394557953, 0.08737186342477798, -0.09148162603378296, -0.25366324186325073, -0.15777793526649475, 0.11410367488861084, 0.06260209530591965, 0.04304129630327225, -0.14828628301620483, -0.2294451892375946, 0.05678379163146019, 0.09197875112295151, -0.010407604277133942, -0.08063007146120071, -0.07396915555000305, -0.05995892733335495, -0.03558085858821869, -0.0022551945876330137, -0.05305355787277222, -0.061808232218027115, -0.008009159937500954, -0.04186220467090607, 0.16818131506443024, 0.08724962174892426, 0.053429871797561646, -0.06625930964946747, 0.02777191624045372, 0.014741811901330948, 0.06751753389835358, -0.109195776283741, 0.04194112867116928, 0.09997013211250305, -0.018427619710564613, -0.019756078720092773, 0.08481235802173615, 0.14248782396316528, 0.26045912504196167, -0.1585889756679535, 0.06640560925006866, 0.16897939145565033, 0.03319912776350975, -0.0007222592830657959, -0.012140536680817604, 0.10896214097738266, -0.04353797063231468, 0.12731198966503143, -0.0824226438999176, 0.019261669367551804, -0.00321205030195415, -0.09981808066368103, -0.019027279689908028, -0.049597881734371185, -0.03421684354543686, -0.01349818054586649, -0.054132625460624695, -0.013814756646752357, -0.042725563049316406, -0.04719272628426552, 0.0010480801574885845, 0.030069097876548767, -0.18262368440628052, -0.056479111313819885, -0.025765283033251762, -0.029863573610782623, 0.05747661739587784, 0.016064785420894623, 0.004278783220797777, 0.07313673198223114, 0.01817420870065689, 0.16518670320510864, 0.1327381730079651, 0.14167189598083496, -0.022692911326885223, 0.28378379344940186, -0.09423431009054184, 0.010061108507215977, 0.1570310890674591, -0.002949340268969536, 0.09737987816333771, 0.007034510374069214, 0.08016426116228104, -0.13173183798789978, 0.060883380472660065, 0.12708789110183716, -0.08918171375989914, 9.821638806152168e-33, 0.06264577805995941, 0.029670411720871925, -0.07094448059797287, 0.15988048911094666, 0.06132223457098007, -0.013609258458018303, -0.06484418362379074, 0.11095696687698364, -0.15660342574119568, -0.0783475860953331, -0.16670984029769897, -0.046918053179979324, 0.0350506454706192, 0.19249454140663147, -0.09349310398101807, -0.039167799055576324, 0.012478189542889595, 0.10335034877061844, 0.07100410014390945, 0.010014116764068604, 0.08506849408149719, -0.060845114290714264, -0.06187886744737625, -0.0017547421157360077, -0.0039114016108214855, 0.1257690042257309, -0.16321344673633575, 0.14486822485923767, 0.09617526829242706, 0.05252771079540253, -0.11502908170223236, -0.04765608161687851, 0.01322346180677414, -0.06470964848995209, -0.13034842908382416, -0.13902659714221954, -0.06297378242015839, -0.12717552483081818, 0.031010085716843605, 0.06618350744247437, 0.14218652248382568, 0.10091307759284973, -0.19041545689105988, 0.08286309242248535, 0.03966505080461502, -0.08276581019163132, -0.07147733867168427, -0.047460347414016724, -0.0900346040725708, -0.08505692332983017, 0.09591980278491974, 0.02901677042245865, 0.027504675090312958, -0.22083957493305206, -0.03596387058496475, 0.03698302432894707, -0.018308987841010094, -0.04103144258260727, -0.011586869135499, 0.012156426906585693, 0.13483615219593048, 0.0832139179110527, 0.03285675868391991, 0.05394841358065605, 0.024383150041103363, -0.07450249046087265, -0.02396058663725853, -0.05516902357339859, -0.11457362025976181, 0.07735936343669891, -0.043002352118492126, -0.07059185206890106, 0.08111991733312607, -0.03000088781118393, 0.1438007950782776, -0.10536631941795349, 0.19386479258537292, 0.05905771255493164, -0.029415033757686615, -0.013090752065181732, -0.180876225233078, -0.013540093787014484, -0.08305557072162628, 0.11847402155399323, 0.015454698354005814, -0.10202082246541977, 0.0058549316599965096, -0.017049960792064667, -0.15239813923835754, -0.11452683806419373, 0.03419480472803116, -0.06874196976423264, -0.040304288268089294, 0.10348369181156158, 0.04582656919956207, -1.1455913908421009e-32, -0.09081770479679108, 0.016320466995239258, -0.008531153202056885, -0.16727112233638763, -0.09510590136051178, 0.015087176114320755, 0.006716439966112375, -0.11627399176359177, 0.2723280191421509, -0.11861839890480042, 0.11579625308513641, 0.017690379172563553, -0.04739009961485863, -0.08779548853635788, -0.10854208469390869, 0.0417994000017643, -0.06902287900447845, -0.02432214468717575, -0.12735119462013245, -0.06346610188484192, 0.10757917165756226, 0.23952442407608032, -0.12759870290756226, 0.022672828286886215, 0.14623653888702393, 0.01360919140279293, 0.11494141072034836, 0.13342955708503723, 0.05234136804938316, -0.11652731895446777, 0.06920664757490158, 0.046812016516923904, -0.16587132215499878, -0.07548823952674866, 0.0008896300569176674, 0.0810522809624672, 0.12377683073282242, -0.28591036796569824, -0.11620500683784485, -0.03728122636675835, 0.051461465656757355, 0.03189404681324959, -0.11027757078409195, 0.15594933927059174, -0.020950380712747574, 0.05750526115298271, 0.11071047931909561, -0.012630848214030266, 0.0984991192817688, 0.05822867155075073, 0.03179663047194481, -0.01949145458638668, 0.01301601342856884, 0.12915246188640594, -0.09923488646745682, -0.04761761426925659, 0.05735546350479126, -0.05980054661631584, -0.06152859330177307, -0.024160679429769516, 0.019388364627957344, 0.07734770327806473, -0.048041488975286484, 0.007089431397616863, 0.05775171518325806, 0.0660584345459938, 0.049016110599040985, -0.07203910499811172, 0.05025748535990715, -0.05747738853096962, -0.020975470542907715, -0.05228806287050247, -0.11158014833927155, 0.06200304999947548, -0.13760173320770264, 0.0117942588403821, 0.0330696664750576, -0.11888852715492249, -0.01083560474216938, -0.1453263908624649, -0.1098959743976593, -0.059568244963884354, -0.061576977372169495, 0.15995922684669495, 0.20279090106487274, -0.011724707670509815, -0.010285668075084686, 0.11896929144859314, 0.08262006938457489, 0.1068333089351654, -0.027179844677448273, -0.12614348530769348, -0.1615118831396103, 0.0792708545923233, -0.013590225949883461, -1.0148509943519457e-07, 0.24212205410003662, -0.04191715270280838, -0.21236665546894073, 0.007667865604162216, -0.012266590259969234, 0.04969687759876251, -0.19819600880146027, 0.001005680300295353, -0.024740565568208694, 0.15198856592178345, -0.14333149790763855, 0.16591478884220123, -0.08221865445375443, -0.04058464616537094, 0.055444516241550446, 0.009006603620946407, 0.0682523250579834, 0.08895538747310638, -0.11536012589931488, -0.03408545255661011, -0.05678703263401985, -0.05274832621216774, -0.03170524537563324, -0.08595652878284454, 0.017778553068637848, -0.26800334453582764, 0.12372729182243347, 0.07398460805416107, 0.11031658202409744, -0.07773157954216003, -0.0549263134598732, 0.053138263523578644, 0.0535605289041996, 0.12651272118091583, 0.010865363292396069, -0.06402714550495148, 0.0715046226978302, 0.16933533549308777, 0.049749329686164856, 0.12561722099781036, 0.08177773654460907, -0.060416754335165024, -0.10068905353546143, -0.005646228790283203, -0.13160911202430725, -0.1089753806591034, -0.057149194180965424, -0.019712135195732117, 0.19369426369667053, 0.062489718198776245, 0.024553291499614716, -0.01068173535168171, 0.10128863155841827, -0.03897354379296303, -0.11865393817424774, 0.20348775386810303, -0.10848863422870636, -0.13843560218811035, 0.08709656447172165, -0.0426272451877594, 0.1333448588848114, 0.00832807831466198, 0.15156066417694092, -0.06874887645244598], "changes": {"1wk": -11.811765782973344}}, {"text": "PREMIUM Denali Therapeutics Trial of Potential ALS Treatment Misses Primary, Secondary Endpoints; Shares Fall After Hours MT Newswires Tue, Jan 7, 2025, 1:30 AM 1 min read In This Article: DNLI -6.27% Denali Therapeutics (DNLI) said Monday the phase 2/3 Healey-ALS platform trial of eIF2B activator DN PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DNLI", "date": "2025-01-07T01:30:28", "sentiment": {"score": 0.005433041602373123, "confidence": 0.039049457758665085, "probabilities": {"positive": 0.039049457758665085, "negative": 0.03361641615629196, "neutral": 0.9273341298103333}}, "embedding": [-0.1044580265879631, -0.2649068534374237, 0.03684699162840843, -0.02884374000132084, -0.04362878575921059, 0.007353372871875763, -0.11911129206418991, 0.09568003565073013, 0.007800743915140629, 0.0017144879093393683, 0.007436778862029314, 0.09817155450582504, -0.07813092321157455, -0.0047335876151919365, 0.034312449395656586, 0.002291731769219041, -0.021627020090818405, -0.01907261647284031, -0.017809176817536354, 0.05817973613739014, -0.09632343053817749, 0.23652973771095276, -0.06685536354780197, 0.0702289417386055, 0.02840546891093254, 0.01719490997493267, -0.12030158191919327, -0.04503043740987778, 0.04026491940021515, -0.1091143786907196, 0.07991527765989304, -0.046588312834501266, 0.07950227707624435, -0.1385263353586197, 0.11341410875320435, -0.04309558868408203, -0.13377971947193146, 0.022218434140086174, -0.13656333088874817, -0.04044905677437782, 0.1252121478319168, -0.03251662477850914, -0.01822497695684433, 0.0013762757880613208, 0.04307662695646286, -0.13820405304431915, -0.2001076489686966, 0.06494562327861786, 0.10181589424610138, 0.10241498053073883, -0.0179184190928936, -0.2033434808254242, 0.2618725299835205, 0.02188025787472725, 0.011446683667600155, 0.05986753851175308, -0.07611345499753952, 0.06868157535791397, -0.05372530221939087, 0.029612014070153236, 0.11225607991218567, -0.09074333310127258, -0.028858844190835953, -0.0281190387904644, -0.006528876721858978, 0.15170474350452423, 0.06702445447444916, -0.024283787235617638, 0.018515639007091522, -0.05465055629611015, -0.08080388605594635, -0.007929939776659012, 0.05218439921736717, 0.031924664974212646, 0.09459858387708664, 0.009924730286002159, 0.07829377800226212, -0.14915883541107178, 0.2429032027721405, -0.09429910778999329, 0.14513301849365234, 0.09099558740854263, 0.058904003351926804, -0.013935746625065804, 0.07724496722221375, 0.010558960027992725, -0.03887752443552017, -0.07316289842128754, -0.12409748136997223, -0.13257421553134918, 0.03901294991374016, -0.08154222369194031, -0.06651098281145096, -0.01607968471944332, -0.054731301963329315, 0.05132729187607765, -0.20099547505378723, 0.06897516548633575, -0.0424923337996006, 0.05608019977807999, 0.027067240327596664, 0.03605027124285698, -0.08692970871925354, -0.2054874449968338, -0.1114569827914238, -0.16210421919822693, 0.09724131971597672, -0.012063369154930115, -0.02607164904475212, 0.14260779321193695, 0.047846611589193344, 0.036855969578027725, 0.026074551045894623, -0.001601913245394826, 0.019812237471342087, 0.32197150588035583, -0.11891258507966995, -0.0026782057248055935, 0.15446323156356812, -0.17212720215320587, -0.015673544257879257, -0.028514668345451355, 0.08317115902900696, -0.11723512411117554, 0.05894662067294121, 0.026359347626566887, -0.17669571936130524, 1.3655397551291915e-32, 0.03741274029016495, -0.07771860063076019, -0.05821773037314415, -0.041647788137197495, 0.0836394801735878, -0.21052084863185883, -0.06457776576280594, 0.06626375764608383, -0.02316674403846264, -0.1636456400156021, -0.20585408806800842, 0.10979369282722473, 0.021663017570972443, 0.028285294771194458, -0.14216957986354828, -0.17562879621982574, -0.04343917593359947, 0.18346622586250305, -0.061552077531814575, -0.0024189159739762545, 0.2078372687101364, -0.05130111053586006, -0.0993594080209732, -0.007110121659934521, -0.07102897763252258, -0.06457233428955078, 0.08161856234073639, 0.1111454963684082, 0.31505951285362244, 0.04047302156686783, -0.18252041935920715, -0.0638890415430069, 0.06287296116352081, -0.07292305678129196, 0.13277097046375275, 0.09318621456623077, -0.05985311046242714, 0.11082345247268677, -0.01413741149008274, 0.03491895645856857, 0.06546961516141891, 0.1033194363117218, -0.16064158082008362, -0.12424999475479126, 0.03079879656434059, -0.07086507976055145, -0.063024140894413, -0.05780774727463722, 0.08455903083086014, -0.07457423210144043, 0.02650577947497368, 0.10424710065126419, -0.07395485043525696, -0.059848181903362274, 0.11611822992563248, 0.06491199880838394, -0.10407046973705292, 0.010687791742384434, 0.20800578594207764, -0.011407802812755108, 0.1014515683054924, 0.025203024968504906, 0.033612966537475586, -0.1348678022623062, -0.13111254572868347, 0.10048548132181168, -0.02120303176343441, -0.1302051693201065, -0.12840595841407776, -0.11358215659856796, 0.1370587944984436, -0.057908087968826294, -0.019894396886229515, 0.07714500278234482, -0.1454167366027832, -0.00063101458363235, 0.0515662282705307, 0.14977629482746124, 0.16508427262306213, 0.025531528517603874, 0.015703190118074417, 0.06303761899471283, -0.08886583149433136, 0.18896834552288055, 0.07688574492931366, -0.026442259550094604, -0.05488886684179306, -0.09208814799785614, -0.2272927612066269, -0.06096421182155609, -0.005034271627664566, 0.09484488517045975, -0.07748688757419586, 0.08847735822200775, 0.14465683698654175, -1.6719624797137606e-32, -0.10534703731536865, 0.13056699931621552, -0.041870515793561935, -0.0683211088180542, -0.022815421223640442, 0.06373771280050278, -0.0018536520656198263, 0.07739275693893433, 0.3384207487106323, 0.03540874645113945, 0.1054665744304657, 0.08339814841747284, -0.0918387919664383, 0.03985721617937088, -0.04838193207979202, -0.004640949424356222, -0.15059812366962433, -0.011196781881153584, -0.11620650440454483, 0.03341837599873543, 0.2634889781475067, 0.21915027499198914, 0.0103352265432477, 0.08817445486783981, 0.0020649656653404236, 0.04289824143052101, 0.107666976749897, 0.16961126029491425, -0.0118239251896739, -0.08658334612846375, -0.043316904455423355, -0.07344157993793488, -0.24484920501708984, -0.09053269028663635, -0.13781054317951202, 0.022722259163856506, 0.03664875775575638, -0.09182163327932358, -0.19589699804782867, -0.07315072417259216, 0.12051808834075928, 0.023279650136828423, 0.08002564311027527, 0.04373274743556976, 0.14915552735328674, -0.06700718402862549, 0.008518095128238201, -0.16381259262561798, 0.0613553524017334, -0.007038944400846958, -0.01257279235869646, -0.13168667256832123, 0.14000827074050903, 0.03150704503059387, -0.12743422389030457, -0.010789045132696629, 0.10463190078735352, -0.009133503772318363, -0.10975327342748642, 0.14536115527153015, -0.026865428313612938, 0.04849237948656082, -0.21969790756702423, -0.05874191224575043, 0.01349034532904625, 0.07353226095438004, 0.07130628824234009, -0.0584033727645874, 0.02826979197561741, -0.06740044802427292, -0.07949162274599075, -0.05672106519341469, -0.13712558150291443, -0.11334006488323212, -0.10725518316030502, 0.0608183927834034, -0.18559694290161133, -0.004203572403639555, 0.01675097830593586, -0.06537115573883057, -0.03394504263997078, -0.04265624284744263, -0.05474761873483658, 0.08077692240476608, -0.03566289693117142, 0.0005630680243484676, 0.10442551970481873, -0.21398186683654785, -0.08019116520881653, 0.1305939108133316, -0.13751429319381714, -0.06247832998633385, -0.09489507228136063, 0.11656011641025543, -0.05682411789894104, -1.0133484096286338e-07, 0.1052255779504776, 0.09369600564241409, 0.10069628059864044, 0.026737792417407036, -0.028151774778962135, -0.1617208570241928, -0.06300554424524307, 0.0378701351583004, -0.05562205985188484, 0.11665435880422592, -0.004433035850524902, 0.0328778438270092, -0.05036458745598793, -0.05129794031381607, 0.0297869723290205, 0.0009036355186253786, 0.04505041986703873, 0.17196549475193024, -0.13093961775302887, -0.19398872554302216, 0.0790880024433136, 0.0158611461520195, 0.13857229053974152, -0.11367406696081161, 0.011370522901415825, -0.024771953001618385, 0.1190221905708313, 0.0982212945818901, 0.00045370752923190594, -0.1507025808095932, -0.07896549254655838, 0.1687854528427124, -0.07021939009428024, -0.005865591578185558, -0.1260048747062683, -0.09267527610063553, 0.04832058027386665, 0.15053704380989075, -0.16799461841583252, 0.12026975303888321, -0.06585519015789032, -0.004606431815773249, 0.045089855790138245, 0.06106136366724968, -0.04580162093043327, -0.015486806631088257, -0.03260423615574837, 0.03936690092086792, 0.1637744903564453, 0.002210257574915886, 0.029631616547703743, -0.045159712433815, 0.07696494460105896, -0.019291888922452927, -0.11593179404735565, 0.184810072183609, -0.07918272167444229, 0.11068081855773926, -0.1169290542602539, 0.06779876351356506, 0.04671264439821243, -0.12008883059024811, -0.01641318015754223, 0.11254143714904785], "changes": {"1wk": -1.1604417042266153}}, {"text": "PREMIUM Baird Initiates Denali Therapeutics at Outperform With $31 Price Target MT Newswires Tue, Jan 7, 2025, 4:17 PM In This Article: DNLI -6.27% Denali Therapeutics (DNLI) has an average rating of buy and mean price target of $40.79, according t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "DNLI", "date": "2025-01-07T16:17:20", "sentiment": {"score": 0.03774150926619768, "confidence": 0.050963789224624634, "probabilities": {"positive": 0.050963789224624634, "negative": 0.013222279958426952, "neutral": 0.9358139038085938}}, "embedding": [-0.2525060772895813, -0.206838920712471, -0.05058704689145088, -0.04392306134104729, -0.14310894906520844, -0.029663771390914917, 0.07713939249515533, 0.29470276832580566, 0.03214758634567261, 0.11840891093015671, -0.12657631933689117, -0.019349198788404465, -0.05847986787557602, 0.1041855439543724, 0.012463247403502464, -0.06821444630622864, 0.1307356208562851, -0.022365471348166466, 0.02156945876777172, 0.05926062539219856, -0.09474669396877289, 0.24631255865097046, -0.06025198474526405, 0.04524412378668785, 0.24438901245594025, 0.01266520656645298, -0.13086308538913727, -0.11548519134521484, 0.041621409356594086, -0.02720610797405243, -0.12179144471883774, -0.06851061433553696, -0.04284118488430977, -0.2311546951532364, 0.09810946136713028, -0.015611404553055763, -0.14797207713127136, 0.10613260418176651, 0.04930148646235466, 0.0674905851483345, 0.13985572755336761, 0.03733548894524574, -0.20437385141849518, -0.06755266338586807, 0.08991999924182892, -0.16773663461208344, -0.1256604939699173, 0.28683701157569885, 0.14604607224464417, 0.06515973806381226, -0.16099441051483154, -0.14387579262256622, 0.18621523678302765, -0.01645755022764206, -0.007035536225885153, -0.057612206786870956, -0.07016279548406601, 0.024509640410542488, -0.012641215696930885, -0.009037473239004612, 0.0701678916811943, -0.1210547685623169, -0.03411976248025894, 0.019498242065310478, 0.17591403424739838, 0.09181925654411316, 0.0027438022661954165, 0.006498954724520445, 0.17650015652179718, -0.11713893711566925, -0.0030944396276026964, -0.007490338291972876, 0.11229860782623291, -0.04737701267004013, -0.05662165582180023, -0.025404559448361397, 0.2139109969139099, -0.13523460924625397, 0.13910724222660065, -0.09086119383573532, 0.17454040050506592, -0.017805540934205055, 0.13106337189674377, 0.09815128892660141, 0.2095075398683548, -0.017938295379281044, 0.15701572597026825, -0.12093082815408707, 0.05736585706472397, -0.09632409363985062, 0.04452846571803093, 0.017851321026682854, -0.17726147174835205, -0.09983635693788528, -0.1548834592103958, 0.054210856556892395, -0.21527324616909027, 0.11058563739061356, -0.07364656031131744, 0.0699419379234314, 0.035617802292108536, -0.02002057246863842, -0.14184118807315826, -0.09223370254039764, -0.1254487782716751, -0.17877314984798431, 0.16702160239219666, 0.014911079779267311, 0.04997674748301506, 0.211761936545372, -0.08023311197757721, 0.023491311818361282, -0.05137527361512184, 0.07768887281417847, -0.051085200160741806, 0.15233558416366577, 0.062294505536556244, -0.07884284108877182, 0.2078329622745514, -0.19764699041843414, -0.07026233524084091, -0.10222306102514267, 0.017821133136749268, -0.015577651560306549, -0.10320320725440979, 0.06187945231795311, -0.051714517176151276, 1.005847006111615e-32, 0.09623480588197708, 0.042770370841026306, -0.17653444409370422, -0.12426354736089706, -0.030551984906196594, -0.06314098834991455, -0.05375029891729355, 0.07664315402507782, -0.13759702444076538, -0.12299908697605133, -0.2769390046596527, 0.09563452005386353, -0.137417271733284, 0.1807258576154709, -0.15717202425003052, -0.08116720616817474, 0.0779532864689827, 0.13488036394119263, 0.0007091198931448162, 0.005177055485546589, 0.04827440157532692, 0.058320432901382446, -0.0984693393111229, -0.004420835990458727, -0.11247975379228592, -0.045102234929800034, -0.006439317483454943, 0.20297642052173615, 0.08319460600614548, 0.00825376808643341, -0.18838128447532654, -0.02759726531803608, 0.1488887518644333, -0.0329245999455452, -0.013308112509548664, -0.06388385593891144, -0.2233390063047409, 0.03535664454102516, 0.05509749799966812, 0.02781565859913826, -0.01819349266588688, 0.2652125060558319, -0.15420684218406677, -0.057912133634090424, 0.014404756017029285, 0.10131388902664185, 0.015342487022280693, -0.11104987561702728, -0.09003391861915588, -0.12108345329761505, -0.06438426673412323, 0.18357904255390167, -0.21765530109405518, 0.03839437663555145, -0.04567190259695053, -0.0756966769695282, -0.09624364227056503, -0.04745671898126602, 0.2443198412656784, 0.18083083629608154, -0.03513828292489052, 0.09323327243328094, 0.11488128453493118, -0.05371326208114624, 0.04030604660511017, 0.07433813810348511, -0.06598322838544846, -0.04895249754190445, -0.033298879861831665, -0.05026678368449211, 0.07458749413490295, 0.03984389081597328, 0.022357042878866196, -0.06367598474025726, 0.05795711278915405, -0.12293814867734909, 0.09624278545379639, 0.09719760715961456, 0.2119101732969284, 0.07365525513887405, 0.08683115243911743, -0.059429656714200974, 0.012222526594996452, 0.10164891183376312, 0.06581176072359085, 0.06862152367830276, -0.016685456037521362, -0.04611428827047348, -0.18513302505016327, -0.11454938352108002, 0.06366517394781113, 0.007210076320916414, -0.09097891300916672, -0.059153780341148376, 0.1717369705438614, -1.1865697116589412e-32, -0.03944539278745651, 0.1275220364332199, 0.041596461087465286, -0.02416563406586647, -0.19883237779140472, 0.08222039043903351, -0.2059587985277176, -0.0034365509636700153, 0.33898913860321045, 0.18220862746238708, 0.10219591110944748, 0.048201531171798706, -0.08334928005933762, 0.18260356783866882, -0.08763868361711502, 0.03979813680052757, -0.0958961471915245, -0.0855870172381401, -0.08874344080686569, -0.20753784477710724, 0.20133048295974731, 0.19593656063079834, -0.08030153810977936, 0.16227670013904572, 0.02954484336078167, -0.030649740248918533, 0.12938018143177032, 0.19186337292194366, -0.07578716427087784, -0.12038610130548477, -0.08370674401521683, 0.04214858263731003, -0.2035573571920395, 0.028166648000478745, -0.1273510456085205, 0.11913253366947174, 0.09548190236091614, -0.05812496691942215, -0.09612416476011276, -0.09516728669404984, 0.09305053949356079, -0.0251283198595047, 0.15204328298568726, 0.021487988531589508, 0.14562684297561646, -0.1738511174917221, -0.017886077985167503, -0.08198820054531097, 0.028820253908634186, 0.14400236308574677, 0.061451494693756104, -0.11445712298154831, 0.1269509494304657, 0.047658178955316544, -0.22399930655956268, -0.04202088713645935, 0.11622563004493713, 0.1384408324956894, -0.058681465685367584, 0.057293932884931564, 0.10530111193656921, 0.09401746839284897, -0.17799651622772217, -0.04110057279467583, -0.00704528670758009, 0.05925799906253815, 0.12236203998327255, -0.09899579733610153, 0.013301169499754906, -0.0912964716553688, -0.024923181161284447, -0.15463890135288239, 0.12371689826250076, -0.1409580260515213, -0.1865590363740921, -0.040435269474983215, -0.02354690246284008, -0.05107608810067177, 0.13995985686779022, -0.11277060955762863, -0.03324385732412338, -0.09949512779712677, -0.053373921662569046, 0.04959368333220482, 0.010388418100774288, -0.015933331102132797, 0.06622538715600967, -0.08015946298837662, -0.22279199957847595, 0.2671535611152649, -0.11605128645896912, -0.12402032315731049, -0.031598396599292755, -0.047186847776174545, 0.027785969898104668, -1.0049679133317113e-07, 0.23452970385551453, 0.04396972432732582, -0.09905382990837097, 0.20695240795612335, -0.008411611430346966, -0.055637385696172714, -0.08656176924705505, -0.00014533447392750531, 0.03257662057876587, 0.16922329366207123, 0.04610682278871536, 0.07758185267448425, -0.07549180835485458, -0.0945294052362442, -0.11771423369646072, -0.03654932603240013, -0.009798099286854267, 0.11890202015638351, -0.04300489276647568, -0.02386101335287094, 0.16196464002132416, 0.04627147316932678, 0.02980673499405384, -0.03969447687268257, -0.00022343022283166647, -0.03299910947680473, 0.1701575666666031, 0.12264019250869751, 0.12508940696716309, -0.13218840956687927, -0.0427921824157238, 0.09021348506212234, 0.1087128147482872, 0.08806969970464706, 0.045759767293930054, -0.1139000877737999, -0.040596701204776764, 0.14623889327049255, -0.15889662504196167, 0.016133202239871025, -0.00850257370620966, -0.19522614777088165, -0.012424780055880547, 0.048792362213134766, -0.08046197146177292, -0.005546526983380318, -0.17107783257961273, 0.02103884518146515, 0.17200131714344025, -0.01727388985455036, 0.10310570150613785, 0.004904288798570633, 0.13483424484729767, 0.02197187766432762, -0.1819739043712616, 0.06614147871732712, -0.11181780695915222, 0.01250525750219822, -0.2043822854757309, 0.17948484420776367, 0.019287046045064926, -0.27671757340431213, -0.0824645459651947, 0.020707467570900917], "changes": {"1wk": -7.507082765241228}}]